[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Qiagen Sciences LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":361},{"warningLetters":4,"total":360},[5,30,54,73,94,114,135,154,173,194,216,237,261,284,304,323,341],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},241,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026\">Prime Sciences\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs Sold Over the Internet","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14500 N. Northsight Blvd, STE 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@prime-sciences.com\"> info@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prime-sciences.com\"> support@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 721805\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prime Sciences:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cagrilintide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\u003C\u002Fp>\u003Cul>\u003Cli>“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\u003C\u002Fli>\u003Cli>“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-R (10MG) (identified as Retatrutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\u003C\u002Fp>\u003Cul>\u003Cli>“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\u003C\u002Fli>\u003Cli>“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-S (10MG) (identified as Semaglutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic – Weight Loss Supplement.”\u003C\u002Fli>\u003Cli>“Semaglutide peptide therapy benefits include:\u003Cbr>o Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\u003Cbr>o Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\u003Cbr>o Reduces blood sugar levels to promote weight loss”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-T (10MG) (identified as Tirzepatide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\u003C\u002Fp>\u003Cul>\u003Cli>“Tirzepatide therapy benefits include:\u003Cbr>o A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\u003Cbr>o Stimulates the production of insulin to lower blood sugar\u003Cbr>o Reduces appetite by slowing the time it takes the stomach to empty”\u003C\u002Fli>\u003Cli>“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MAZDUTIDE (10MG)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide peptide therapy benefits include:\u003Cbr>o Weight Management\u003Cbr>􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\u003C\u002Fli>\u003Cli>“Improved metabolic health\u003Cbr>o Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\u003Cbr>o Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\u003Cbr>o Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BAC water\u003C\u002Fu>\u003Cbr>Your firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\u003C\u002Fp>\u003Cp>Your Prime Sciences products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPrime Sciences\n\n14500 N. Northsight Blvd, STE 100\n\nScottsdale, AZ 85260\n\nUnited States\n\ninfo@prime-sciences.com\n\nsupport@prime-sciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 721805\nPrime Sciences:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nDespite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\nExamples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nCagrilintide\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\n“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\n“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-R (10MG) (identified as Retatrutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\n“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\n“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\nGLP1-S (10MG) (identified as Semaglutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\n“Ozempic – Weight Loss Supplement.”\n“Semaglutide peptide therapy benefits include:\no Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\no Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\no Reduces blood sugar levels to promote weight loss”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-T (10MG) (identified as Tirzepatide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\n“Tirzepatide therapy benefits include:\no A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\no Stimulates the production of insulin to lower blood sugar\no Reduces appetite by slowing the time it takes the stomach to empty”\n“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\nMAZDUTIDE (10MG)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\n“Mazdutide peptide therapy benefits include:\no Weight Management\n􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\n“Improved metabolic health\no Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\no Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\no Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\nBAC water\nYour firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\nYour Prime Sciences products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Sciences","prime-sciences-721805-03312026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026","2026-10-26T08:09:44.094362+00:00","Warning Letter","Issued","2026-04-07","721805","Drugs","2026-08-19T04:49:30.204+00:00","Via Email","2026-03-31",{"id":31,"raw":32,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":36,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2429,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022\">BioLab Sciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 621465\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert D. Maguire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLab Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13825 N. Northsight Blvd., Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 23, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Maguire:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\u003C\u002Fp>\n\n\u003Cp>Because Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deficiencies, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture over&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Fluid Flow™, Amnio Restore™,\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of these products since June 22, 2021.\u003C\u002Fp>\n\n\u003Cp>c. Your Fluid Flow™ \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, entitled “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You did not assess the impact of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\u003C\u002Fp>\n\n\u003Cp>d. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel monitoring is required only every \u003Cstrong>(b)(4)\u003C\u002Fstrong> for personnel who process your amniotic fluid products.\u003C\u002Fp>\n\n\u003Cp>e. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\u003C\u002Fp>\n\n\u003Cp>f. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\u003C\u002Fp>\n\n\u003Cp>g. Your written environmental monitoring procedure now describes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca>www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your BSCs.\u003Cbr>\n\u003Cbr>\nb. Your firm has not adequately established and followed written procedures for cleaning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to clean the BSCs during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. In accordance with your cleanroom cleaning procedure, a \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>cleaning of all contact surfaces in the cleanrooms is required at the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> processing operations. However, a review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You failed to ensure sufficient use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified \u003Cem>Bacillus\u003C\u002Fem>, species, a spore-forming organism, on your cleanroom floors. You noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. Your written procedure for cleanroom cleaning does not include the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)].\u003C\u002Fstrong> For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its&nbsp;\u003C\u002Fstrong>\u003Cstrong>specifications whether or not the batch has been already distributed [21 CFR 211.192].\u003C\u002Fstrong> For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include \u003Cem>Bacillus\u003C\u002Fem> species non-anthracis, \u003Cem>Fictibacillus\u003C\u002Fem> species, \u003Cem>Bacillus pumilus\u003C\u002Fem>, Gram Positive Cocci, fungi, and \u003Cem>Bacillus megaterium\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\u003C\u002Fp>\n\n\u003Cp>b. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\u003C\u002Fp>\n\n\u003Cp>c. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid Flow™, and Amnio Restore™.\u003C\u002Fp>\n\n\u003Cp>Your responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\u003C\u002Fp>\n\n\u003Cp>We note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\u003C\u002Fp>\n\n\u003Cp>Finally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Robert D. Maguire\u003Cbr>\nPresident and Chief Executive Officer\u003Cbr>\nBioLab Sciences, Inc.\u003Cbr>\n7662 East Gray Road, Suite 107\u003Cbr>\nScottsdale, AZ 85260\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Some of your products are the same products marketed under different brand names. For example, you represented to FDA that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\nOBPO 621465\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobert D. Maguire\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n13825 N. Northsight Blvd., Suite 101\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 23, 2022\n\nDear Mr. Maguire:\n\nDuring an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).1,2 You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\n\nMyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\n\nBased on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\n\nMyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\n\nAn HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are (b)(4) prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\n\nBecause Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].3\n\nPlease be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and (b)(4), are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act.\n\nIn order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\n\nYour CGMP deficiencies, involving over (b)(4) units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\n\n1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture over (b)(4) units of Fluid Flow™, Amnio Restore™,(b)(4), Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\n\nb. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over (b)(4) units of these products since June 22, 2021.\n\nc. Your Fluid Flow™ (b)(4) sterilization validation, entitled “(b)(4) Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\n\ni. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\n\nii. You did not assess the impact of the (b)(4) sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\n\nd. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\n\ni. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\n\nii. Personnel monitoring is required only every (b)(4) for personnel who process your amniotic fluid products.\n\ne. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\n\nf. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\n\ng. Your written environmental monitoring procedure now describes that (b)(4) colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your BSCs.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the (b)(4) BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the (b)(4) when (b)(4) is used to clean the BSCs during (b)(4) cleanings.\n\n4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your cleanrooms.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\n\ni. In accordance with your cleanroom cleaning procedure, a (b)(4) cleaning of all contact surfaces in the cleanrooms is required at the (b)(4) processing operations. However, a review of your (b)(4) cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\n\nii. You failed to ensure sufficient use of (b)(4), a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified Bacillus, species, a spore-forming organism, on your cleanroom floors. You noted that (b)(4) was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\n\niii. Your written procedure for cleanroom cleaning does not include the (b)(4) when (b)(4) is used during (b)(4) cleanings.\n\niv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\n\n5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)]. For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\n\n6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192]. For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include Bacillus species non-anthracis, Fictibacillus species, Bacillus pumilus, Gram Positive Cocci, fungi, and Bacillus megaterium.\n\n7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84]. For example:\n\na. Your firm used (b)(4) to manufacture approximately (b)(4) batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\n\nb. Your firm used (b)(4), to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\n\nc. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\n\n8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\n\nWe have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\n\nWe acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.4 You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing (b)(4), Stimuleyes™, Fluid Flow™, and Amnio Restore™.\n\nYour responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\n\nWe note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\n\nFinally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Robert D. Maguire\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n7662 East Gray Road, Suite 107\n\nScottsdale, AZ 85260\n\n_________________________\n\n1 This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\n\n2 Some of your products are the same products marketed under different brand names. For example, you represented to FDA that (b)(4) is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\n\n3 As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. (b)(4).\n\n4 We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.","BioLab Sciences, Inc.","biolab-sciences-inc-621465-08232022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022","2026-10-26T08:08:04.986053+00:00","2022-09-20","621465","Biologics","Robert D. Maguire","2026-08-20T01:33:07.944+00:00","VIA UNITED PARCEL SERVICE","OBPO 621465","2022-08-23",{"id":55,"raw":56,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":18,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},473,[57,58,59,11,60,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-10T05:00:00Z\">11\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fverdure-sciences-inc-717259-11102025\">Verdure Sciences, Inc.\u003C\u002Fa>","Sponsor\u002FInvestigator","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ajay S. Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Verdure Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17150 Metro Park Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Noblesville\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46060-4051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 25-HFD-45-11-01\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 25 and July 12, 2024. The investigators representing FDA reviewed the role of Verdure Sciences, Inc. (Verdure) as the sponsor of a clinical investigation (Protocol 005, “Randomized, Double-Blind Evaluation of Maple leaf extract (Maplifa for Photoaging”) of the investigational drug Maplifa® (1% or 5%).\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 24, 2024, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 24, 2024, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20(a) and (b) and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2. Verdure failed to comply with these requirements. Specifically, Verdure initiated Protocol 005, a clinical investigation of the investigational drug Maplifa®, which is subject to section 505 of the FD&amp;C Act [21 U.S.C. 355], without submitting and having in effect an IND.\u003C\u002Fp>\u003Cp>In Verdure’s July 24, 2024, written response to the Form FDA 483, you stated that Verdure did not believe an IND was required because Protocol 005 assessed the use of topical Maplifa® skin regimen on the cosmetic appearance of skin photoaging (wrinkles and skin brightness). You further stated that the study ingredient was not being studied for use to affect the structure or function of the body or to prevent, treat, mitigate, cure, or diagnose a disease because Protocol 005’s primary endpoint was to detect change in skin brightness as measured by a skin colorimeter and facial photographic image analysis, which are widely used to study the efficacy of cosmetic formulations. Furthermore, you stated that the study met all the IND exemption requirements as listed in an FDA proposed rule\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> that proposed exemptions for certain clinical investigations of products lawfully marketed as a food or cosmetic when the product is to be studied to evaluate its use as a drug. Finally, you stated that Verdure signed a Clinical Study Agreement (CSA) with a third-party vendor to conduct Protocol 005, and the CSA transferred the obligation of the “sponsor” to this third party.\u003C\u002Fp>\u003Cp>We address your arguments below.\u003C\u002Fp>\u003Cp>1. Protocol 005 was a clinical investigation of a drug subject to 21 CFR 312.\u003C\u002Fp>\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines \u003Cem>drug\u003C\u002Fem>, in part, as “articles (other than food) intended to affect the structure or any function of the body of man or other animals….” Whether an investigational article is a drug depends on the intended use of the article in the investigation. Based on Protocol 005 and the final study report, the investiga-tional product, Maplifa®, as used in this clinical investigation, was a drug as defined in section 201(g)(1) of the FD&amp;C Act because Maplifa® was studied for use in the mitigation or treatment of facial wrinkles, skin brightness, skin redness, erythema, and hyperpigmentation.\u003C\u002Fp>\u003Cp>Specifically, as described in the protocol, the objective of Protocol 005 was to “examine the effects of topical Maplifa® on facial wrinkles, redness, and pigmentation.” The final study report for Protocol 005 also stated that “Maplifa® is a proprietary, standardized, phenolic-enriched A[cer] \u003Cem>rubrum\u003C\u002Fem> extract formula that is intended to whiten skin and reduce wrinkle production, primarily due to its anti-oxidative and anti-glycating properties.” The final study report further stated, “To further understand the influence of applying topical \u003Cem>A. rubrum\u003C\u002Fem>-based products to the skin, we conducted a randomized, double-blind evaluation to explore the influence of [glucitol-core containing gallotannins] on reduction of face redness, hyperpigmen-tation, and wrinkle formation.” According to the protocol and the final study report, to assess the efficacy of Maplifa®, Protocol 005’s outcome measures included changes in skin brightness, pigmentation, erythema, redness, and wrinkles. These outcomes were measured using different methods, including skin colorimeter, image-based analysis, and in-person clinical assessments. Therefore, Protocol 005 collected study data to assess the effect of Maplifa® on the skin, as measured by methods including skin colorimeter and facial photographic image analysis.\u003C\u002Fp>\u003Cp>Considering the nature of the study, as described above, we conclude that the evidence collected during the inspection shows that Maplifa® was intended to affect the structure or function of the body; it was not merely intended to affect cosmetic appearance. Maplifa® was therefore intended for use as a drug for the clinical investigation conducted under Protocol 005. As a result, you were required to submit an IND before conducting the clinical investigation.\u003C\u002Fp>\u003Cp>\u003Cem>2. The clinical investigation conducted under Protocol 005 does not meet the exemption criteria in 21 CFR 312.2(b)(1) and is subject to the IND requirements under 21 CFR 312.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit an IND before conducting a clinical investigation of a drug in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2(b). Under 21 CFR 312.2(b)(1), the clinical investigation of a lawfully marketed drug product in the United States is exempt from the IND regulations for a clinical investigation if all the exemption criteria in 21 CFR 312.2(b) are met.\u003C\u002Fp>\u003Cp>Protocol 005 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must be lawfully marketed in the United States as a drug product. Verdure’s July 24, 2024, written response claims that Maplifa® is marketed only as a cosmetic ingredient, not as a drug product. However, as described above, the intended use of Maplifa® under Protocol 005 was as a drug, and we are not aware of any basis to conclude that it is a lawfully marketed drug. You also argue that Maplifa® is exempt from the IND requirements based on an FDA proposed rule. However, your response provided no reasoning to support this assertion. A proposed rule, until final, is not binding and does not supersede or otherwise change existing FDA regulations regarding IND exemptions. Your response also did not explain why Protocol 005 would have qualified for an exemption, even if the proposed rule were final and in effect. Moreover, we note that study participants received the study drug and the study was completed before FDA proposed the regulation at issue for public comment. As explained above, the study materials for Protocol 005 establish that Maplifa®’s intended use in the clinical trial was that of a drug. Further, Protocol 005 was not exempt from 21 CFR 312, and Verdure was required to submit an IND before initiating a clinical investigation of a drug in human subjects.\u003C\u002Fp>\u003Cp>\u003Cem>3. Verdure is the sponsor of the clinical investigation conducted under Protocol 005 as defined in 21 CFR 312.3.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA regulations define a sponsor as a person who takes responsibility for and initiates a clinical investigation [see 21 CFR 312.3]. Under 21 CFR 312.52, a sponsor may transfer responsibility for any or all of its obligations to a Contract Research Organization (CRO) and must describe any such transfer, including the specific obligations transferred, in writing; however, if all obligations are transferred, a general statement that all obligations have been transferred is acceptable. Both the CSA and the work order collected during the inspection and provided in your written response identify Verdure Sciences, Inc., as the “Sponsor” and the third-party vendor as the “Service Provider.” Neither of these documents describes which of Verdure’s sponsor obligations for conducting this study, if any, were transferred to the third-party vendor. Additionally, the CSA and work order do not contain any general statements that sponsor obligations have been transferred. Your written response refers to a provision of the CSA, which states that the third-party vendor “will conduct the Study according to the provisions of the Protocol and this Agreement and in conformance with all [Applicable Laws].” This provision does not describe, in either general or specific terms, any obligations that transferred from you to the third-party vendor.\u003C\u002Fp>\u003Cp>In your written response, you stated that as a corrective and preventive action, Verdure will ensure that all third parties, such as a CRO, comply with all applicable FDA regulations, including filing for an IND, unless exempt. However, your written response is inadequate because it does not provide sufficient details of a corrective and preventive action plan for developing and implementing procedures that comply with IND regulations, should Verdure decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Verdure will comply with IND regulations in the future.\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for complying with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation, and it is Verdure’s responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Verdure’s failure to submit, and to have in effect, an IND before initiating Protocol 005 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Federal Register Proposed Rule - December 9, 2022.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAjay S. Patel\n\nRecipient Title\n\nCEO\n\nVerdure Sciences, Inc.\n\n17150 Metro Park Court\n\nNoblesville, IN 46060-4051\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 25-HFD-45-11-01\n\nDear Mr. Patel:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 25 and July 12, 2024. The investigators representing FDA reviewed the role of Verdure Sciences, Inc. (Verdure) as the sponsor of a clinical investigation (Protocol 005, “Randomized, Double-Blind Evaluation of Maple leaf extract (Maplifa for Photoaging”) of the investigational drug Maplifa® (1% or 5%).\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 24, 2024, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 24, 2024, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\nYou failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\nFDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20(a) and (b) and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2. Verdure failed to comply with these requirements. Specifically, Verdure initiated Protocol 005, a clinical investigation of the investigational drug Maplifa®, which is subject to section 505 of the FD&C Act [21 U.S.C. 355], without submitting and having in effect an IND.\nIn Verdure’s July 24, 2024, written response to the Form FDA 483, you stated that Verdure did not believe an IND was required because Protocol 005 assessed the use of topical Maplifa® skin regimen on the cosmetic appearance of skin photoaging (wrinkles and skin brightness). You further stated that the study ingredient was not being studied for use to affect the structure or function of the body or to prevent, treat, mitigate, cure, or diagnose a disease because Protocol 005’s primary endpoint was to detect change in skin brightness as measured by a skin colorimeter and facial photographic image analysis, which are widely used to study the efficacy of cosmetic formulations. Furthermore, you stated that the study met all the IND exemption requirements as listed in an FDA proposed rule1 that proposed exemptions for certain clinical investigations of products lawfully marketed as a food or cosmetic when the product is to be studied to evaluate its use as a drug. Finally, you stated that Verdure signed a Clinical Study Agreement (CSA) with a third-party vendor to conduct Protocol 005, and the CSA transferred the obligation of the “sponsor” to this third party.\nWe address your arguments below.\n1. Protocol 005 was a clinical investigation of a drug subject to 21 CFR 312.\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles (other than food) intended to affect the structure or any function of the body of man or other animals….” Whether an investigational article is a drug depends on the intended use of the article in the investigation. Based on Protocol 005 and the final study report, the investiga-tional product, Maplifa®, as used in this clinical investigation, was a drug as defined in section 201(g)(1) of the FD&C Act because Maplifa® was studied for use in the mitigation or treatment of facial wrinkles, skin brightness, skin redness, erythema, and hyperpigmentation.\nSpecifically, as described in the protocol, the objective of Protocol 005 was to “examine the effects of topical Maplifa® on facial wrinkles, redness, and pigmentation.” The final study report for Protocol 005 also stated that “Maplifa® is a proprietary, standardized, phenolic-enriched A[cer] rubrum extract formula that is intended to whiten skin and reduce wrinkle production, primarily due to its anti-oxidative and anti-glycating properties.” The final study report further stated, “To further understand the influence of applying topical A. rubrum-based products to the skin, we conducted a randomized, double-blind evaluation to explore the influence of [glucitol-core containing gallotannins] on reduction of face redness, hyperpigmen-tation, and wrinkle formation.” According to the protocol and the final study report, to assess the efficacy of Maplifa®, Protocol 005’s outcome measures included changes in skin brightness, pigmentation, erythema, redness, and wrinkles. These outcomes were measured using different methods, including skin colorimeter, image-based analysis, and in-person clinical assessments. Therefore, Protocol 005 collected study data to assess the effect of Maplifa® on the skin, as measured by methods including skin colorimeter and facial photographic image analysis.\nConsidering the nature of the study, as described above, we conclude that the evidence collected during the inspection shows that Maplifa® was intended to affect the structure or function of the body; it was not merely intended to affect cosmetic appearance. Maplifa® was therefore intended for use as a drug for the clinical investigation conducted under Protocol 005. As a result, you were required to submit an IND before conducting the clinical investigation.\n2. The clinical investigation conducted under Protocol 005 does not meet the exemption criteria in 21 CFR 312.2(b)(1) and is subject to the IND requirements under 21 CFR 312.\nFDA regulations require a sponsor to submit an IND before conducting a clinical investigation of a drug in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2(b). Under 21 CFR 312.2(b)(1), the clinical investigation of a lawfully marketed drug product in the United States is exempt from the IND regulations for a clinical investigation if all the exemption criteria in 21 CFR 312.2(b) are met.\nProtocol 005 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must be lawfully marketed in the United States as a drug product. Verdure’s July 24, 2024, written response claims that Maplifa® is marketed only as a cosmetic ingredient, not as a drug product. However, as described above, the intended use of Maplifa® under Protocol 005 was as a drug, and we are not aware of any basis to conclude that it is a lawfully marketed drug. You also argue that Maplifa® is exempt from the IND requirements based on an FDA proposed rule. However, your response provided no reasoning to support this assertion. A proposed rule, until final, is not binding and does not supersede or otherwise change existing FDA regulations regarding IND exemptions. Your response also did not explain why Protocol 005 would have qualified for an exemption, even if the proposed rule were final and in effect. Moreover, we note that study participants received the study drug and the study was completed before FDA proposed the regulation at issue for public comment. As explained above, the study materials for Protocol 005 establish that Maplifa®’s intended use in the clinical trial was that of a drug. Further, Protocol 005 was not exempt from 21 CFR 312, and Verdure was required to submit an IND before initiating a clinical investigation of a drug in human subjects.\n3. Verdure is the sponsor of the clinical investigation conducted under Protocol 005 as defined in 21 CFR 312.3.\nFDA regulations define a sponsor as a person who takes responsibility for and initiates a clinical investigation [see 21 CFR 312.3]. Under 21 CFR 312.52, a sponsor may transfer responsibility for any or all of its obligations to a Contract Research Organization (CRO) and must describe any such transfer, including the specific obligations transferred, in writing; however, if all obligations are transferred, a general statement that all obligations have been transferred is acceptable. Both the CSA and the work order collected during the inspection and provided in your written response identify Verdure Sciences, Inc., as the “Sponsor” and the third-party vendor as the “Service Provider.” Neither of these documents describes which of Verdure’s sponsor obligations for conducting this study, if any, were transferred to the third-party vendor. Additionally, the CSA and work order do not contain any general statements that sponsor obligations have been transferred. Your written response refers to a provision of the CSA, which states that the third-party vendor “will conduct the Study according to the provisions of the Protocol and this Agreement and in conformance with all [Applicable Laws].” This provision does not describe, in either general or specific terms, any obligations that transferred from you to the third-party vendor.\nIn your written response, you stated that as a corrective and preventive action, Verdure will ensure that all third parties, such as a CRO, comply with all applicable FDA regulations, including filing for an IND, unless exempt. However, your written response is inadequate because it does not provide sufficient details of a corrective and preventive action plan for developing and implementing procedures that comply with IND regulations, should Verdure decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Verdure will comply with IND regulations in the future.\nAs a sponsor, you are responsible for complying with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation, and it is Verdure’s responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Verdure’s failure to submit, and to have in effect, an IND before initiating Protocol 005 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n\u002FS\u002F\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 Federal Register Proposed Rule - December 9, 2022.","Verdure Sciences, Inc.","verdure-sciences-inc-717259-11102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fverdure-sciences-inc-717259-11102025","2026-10-26T08:10:27.247507+00:00","2025-11-18","717259","Ajay S. Patel","2026-08-19T14:55:40.536+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2025-11-10",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":43,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":26,"closeout_date":19,"issuing_office":89,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},2489,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2022-08-30T04:00:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-25T04:00:00Z\">08\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepisciences-inc-631902-08252022\">Episciences Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chad M. Thayer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Episciences Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10211 West Emerald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83704-8987\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 25, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Thayer:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Episciences Inc., FEI 3006435842, at 10211 West Emerald Street, Boise, from March 7 to 11, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 17, 2022, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations into out-of-specification (OOS) laboratory results are inadequate because they do not include scientifically supported conclusions and lack corrective actions and preventive actions (CAPA). For example:\u003C\u002Fp>\n\n\u003Cp>A. Your investigation into bulk drug product assay OOS result of active ingredient zinc oxide reported by your contract testing laboratory for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” Sunscreen, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was inadequate. You determined the root cause to be sampling error and attributed it to a non-homogenous blending sample collected from the “top of the mixer scrapings.” The bulk batch was subsequently resampled, retested for assay, and released after obtaining passing results. Your investigation lacked hypothesis testing and adequate evidence to identify the root cause and you did not document whether other batches and drug products manufactured in your facility were affected. In addition, your investigation failed to address the non-homogeneity of your products based on where test samples are collected.\u003C\u002Fp>\n\n\u003Cp>B. Your investigation into OOS bulk test results for appearance and viscosity for “Purifying Wash,” Lot #s 21A044, 21A045, 21A046, and 21A085, reported by your contract testing laboratory was inadequate. You failed to adequately determine the root cause for these failures. Instead, you inspected sample tubes from each lot for appearance, retested only one of the four lots for assay and subsequently released all four lots on the basis of this limited testing.\u003C\u002Fp>\n\n\u003Cp>You failed to identify appropriate CAPA for these investigations to prevent recurrence of such events. There is no assurance that all batches produced under inadequate conditions have been thoroughly evaluated, and that your firm has identified all significant variables associated with your manufacturing process.\u003C\u002Fp>\n\n\u003Cp>Moreover, your standard operating procedure (SOP) titled “Out of Specification Investigations,” states that batches may be released with OOS results at the discretion of the Quality Assurance (QA) manager.\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document, \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at:&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you revised your OOS investigation SOP to include elements of FDA’s guidance. Your response is inadequate because it provided no assurance that these discrepancies were fully investigated and corrected. There is also no assurance that you conducted a comprehensive investigation into your manufacturing operation (e.g., equipment design, process capability) and that other potentially affected batches or products were evaluated. Furthermore, you failed to perform a risk assessment for the drug products released with inadequate OOS investigations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS including in-process and release\u002Fstability testing results for US products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; ο Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; ο For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; ο For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; ο Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; ο Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; ο Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; ο Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; ο Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; ο Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A risk assessment for the products released to market with inadequate OOS investigations, for all batches that are within expiry.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) &amp; 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate the drug manufacturing processes for your Over-the-Counter (OTC) drug products. For example:\u003C\u002Fp>\n\n\u003Cp>Your records from the last two years showed \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of “Purifying Wash” were OOS for appearance and \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots were OOS for viscosity, which affirms the inconsistent performance of your inadequately validated process.\u003C\u002Fp>\n\n\u003Cp>You did not follow your validation procedure, which identifies critical quality attributes such as pH, viscosity, micelle size, color, odor, appearance, and Active Pharmaceutical Ingredient (API) concentration. Specifically, the Process Validation Report PV02.002R001 for “Epionce Purifying Wash Blemish Tx” included only API concentration and microbiology test results but did not include results for any other critical quality attributes. Your validation report lacks demonstration of homogeneity across batches, which could be impacted by other critical quality attributes and influential factors, including but not limited to, mixing speeds and times. However, a meaningful evaluation of these critical control parameters was not included in your validation report.\u003C\u002Fp>\n\n\u003Cp>Your firm lacks an adequate process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In your response you acknowledged the violation, revised the SOP titled “Validation Procedure,” to include performance parameters, and committed to revalidate manufacturing processes for all your drug products in accord with the FDA guidance document.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not perform a risk assessment and provide a mitigation plan for the drug products you produced and distributed using inadequately validated processes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>A risk assessment for the distributed drug product produced using inadequately validated process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to perform, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) &amp; 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate release testing for each batch of your drug products prior to their distribution. During the inspection, you stated that finished product assay and microbiological release testing is performed only on batches that are placed on stability studies. In the last two years you manufactured and released approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of “Purifying Wash”, and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of “Daily Shield Tinted SPF 50”. However, you conducted full testing only for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of each product that were placed on stability studies.\u003C\u002Fp>\n\n\u003Cp>In your Process Validation Report PV02.001R001 for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and Report PV02.002R001 for “Purifying Wash Blemish Tx,” you concluded that \"Active ingredient indicates consistency enough to justify specification change from release test to one lot per quarter stability test.\" Also, your SOP titled “QA Finished Product Testing for Release,” requires \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but only for certain products. Your failure to perform microbiological testing on each lot of finished drug product is a repeat observation from the FDA inspection conducted in 2017.\u003C\u002Fp>\n\n\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all pre-determined quality attributes and are appropriate for their intended use, including microbiological specifications. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you updated SOPs requiring assay and microbiological release testing for each batch of your finished drug products, and you plan to perform the assay and microbiological testing on retain samples of previously released drug product batches that were still within expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) &amp; 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not perform identity testing on each component lot prior to use in manufacture of your drug product. Several API lots were released into production without performing adequate acceptance testing, including identity.\u003C\u002Fp>\n\n\u003Cp>In addition, you have not adequately established the reliability of your raw material suppliers, including your API suppliers. During the inspection you acknowledged that you have not qualified your suppliers.\u003C\u002Fp>\n\n\u003Cp>In your response you state that you revised your SOP to include identity testing for API and plan to test retain samples of previously released lots of components. You revised the SOP to require full testing of one random lot of API annually.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you do not provide a detailed plan to establish supplier reliability. Random lot testing alone is not sufficient to establish supplier reliability.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificate of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A risk assessment of components released without testing for purity, strength and quality, and used in manufacturing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Jamie Dion, Compliance Officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chad M. Thayer\n\nRecipient Title\n\nChief Operating Officer\n\nEpisciences Inc.\n\n10211 West Emerald Street\n\nBoise, ID 83704-8987\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nAugust 25, 2022\n\nDear Mr. Thayer:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Episciences Inc., FEI 3006435842, at 10211 West Emerald Street, Boise, from March 7 to 11, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 17, 2022, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether the batch has already been distributed (21 CFR 211.192).\n\nYour investigations into out-of-specification (OOS) laboratory results are inadequate because they do not include scientifically supported conclusions and lack corrective actions and preventive actions (CAPA). For example:\n\nA. Your investigation into bulk drug product assay OOS result of active ingredient zinc oxide reported by your contract testing laboratory for “(b)(4)” Sunscreen, Lot # (b)(4), was inadequate. You determined the root cause to be sampling error and attributed it to a non-homogenous blending sample collected from the “top of the mixer scrapings.” The bulk batch was subsequently resampled, retested for assay, and released after obtaining passing results. Your investigation lacked hypothesis testing and adequate evidence to identify the root cause and you did not document whether other batches and drug products manufactured in your facility were affected. In addition, your investigation failed to address the non-homogeneity of your products based on where test samples are collected.\n\nB. Your investigation into OOS bulk test results for appearance and viscosity for “Purifying Wash,” Lot #s 21A044, 21A045, 21A046, and 21A085, reported by your contract testing laboratory was inadequate. You failed to adequately determine the root cause for these failures. Instead, you inspected sample tubes from each lot for appearance, retested only one of the four lots for assay and subsequently released all four lots on the basis of this limited testing.\n\nYou failed to identify appropriate CAPA for these investigations to prevent recurrence of such events. There is no assurance that all batches produced under inadequate conditions have been thoroughly evaluated, and that your firm has identified all significant variables associated with your manufacturing process.\n\nMoreover, your standard operating procedure (SOP) titled “Out of Specification Investigations,” states that batches may be released with OOS results at the discretion of the Quality Assurance (QA) manager.\n\nFor more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\n\nIn your response, you stated that you revised your OOS investigation SOP to include elements of FDA’s guidance. Your response is inadequate because it provided no assurance that these discrepancies were fully investigated and corrected. There is also no assurance that you conducted a comprehensive investigation into your manufacturing operation (e.g., equipment design, process capability) and that other potentially affected batches or products were evaluated. Furthermore, you failed to perform a risk assessment for the drug products released with inadequate OOS investigations.\n\nIn response to this letter, provide the following:\n\nA retrospective, independent review of all invalidated OOS including in-process and release\u002Fstability testing results for US products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\n\nο Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\nο For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\nο For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\nο Quality unit oversight of laboratory investigations\n\nο Identification of adverse laboratory control trends\n\nο Resolution of causes of laboratory variation\n\nο Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\nο Adequately scoping of each investigation and its CAPA\n\nο Revised OOS investigation procedures with these and other remediations\n\nA risk assessment for the products released to market with inadequate OOS investigations, for all batches that are within expiry.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) & 211.100(b)).\n\nYou failed to adequately validate the drug manufacturing processes for your Over-the-Counter (OTC) drug products. For example:\n\nYour records from the last two years showed (b)(4) lots of “Purifying Wash” were OOS for appearance and (b)(4) lots were OOS for viscosity, which affirms the inconsistent performance of your inadequately validated process.\n\nYou did not follow your validation procedure, which identifies critical quality attributes such as pH, viscosity, micelle size, color, odor, appearance, and Active Pharmaceutical Ingredient (API) concentration. Specifically, the Process Validation Report PV02.002R001 for “Epionce Purifying Wash Blemish Tx” included only API concentration and microbiology test results but did not include results for any other critical quality attributes. Your validation report lacks demonstration of homogeneity across batches, which could be impacted by other critical quality attributes and influential factors, including but not limited to, mixing speeds and times. However, a meaningful evaluation of these critical control parameters was not included in your validation report.\n\nYour firm lacks an adequate process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\n\nIn your response you acknowledged the violation, revised the SOP titled “Validation Procedure,” to include performance parameters, and committed to revalidate manufacturing processes for all your drug products in accord with the FDA guidance document.\n\nYour response is inadequate because you did not perform a risk assessment and provide a mitigation plan for the drug products you produced and distributed using inadequately validated processes.\n\nIn response to this letter, provide the following:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\nInclude your process performance protocols, and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nA risk assessment for the distributed drug product produced using inadequately validated process.\n\n3. Your firm failed to perform, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) & 211.165(b)).\n\nYou failed to perform adequate release testing for each batch of your drug products prior to their distribution. During the inspection, you stated that finished product assay and microbiological release testing is performed only on batches that are placed on stability studies. In the last two years you manufactured and released approximately (b)(4) batches of “Purifying Wash”, and approximately (b)(4) batches of “Daily Shield Tinted SPF 50”. However, you conducted full testing only for approximately (b)(4) batches of each product that were placed on stability studies.\n\nIn your Process Validation Report PV02.001R001 for “(b)(4)” and Report PV02.002R001 for “Purifying Wash Blemish Tx,” you concluded that \"Active ingredient indicates consistency enough to justify specification change from release test to one lot per quarter stability test.\" Also, your SOP titled “QA Finished Product Testing for Release,” requires (b)(4), but only for certain products. Your failure to perform microbiological testing on each lot of finished drug product is a repeat observation from the FDA inspection conducted in 2017.\n\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all pre-determined quality attributes and are appropriate for their intended use, including microbiological specifications. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release.\n\nWe acknowledge that you updated SOPs requiring assay and microbiological release testing for each batch of your finished drug products, and you plan to perform the assay and microbiological testing on retain samples of previously released drug product batches that were still within expiry.\n\nIn response to this letter, provide the following:\n\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n4. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).\n\nYou did not perform identity testing on each component lot prior to use in manufacture of your drug product. Several API lots were released into production without performing adequate acceptance testing, including identity.\n\nIn addition, you have not adequately established the reliability of your raw material suppliers, including your API suppliers. During the inspection you acknowledged that you have not qualified your suppliers.\n\nIn your response you state that you revised your SOP to include identity testing for API and plan to test retain samples of previously released lots of components. You revised the SOP to require full testing of one random lot of API annually.\n\nYour response is inadequate because you do not provide a detailed plan to establish supplier reliability. Random lot testing alone is not sufficient to establish supplier reliability.\n\nIn response to this letter, provide the following:\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificate of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA risk assessment of components released without testing for purity, strength and quality, and used in manufacturing.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact Jamie Dion, Compliance Officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter\n\nDirector, Division of Pharmaceutical Quality Operations IV","Episciences Inc.","episciences-inc-631902-08252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepisciences-inc-631902-08252022","2026-10-26T08:08:35.999752+00:00","2022-08-30","631902","Division of Pharmaceutical Quality Operations IV","Mr. Chad M. Thayer","2026-08-20T01:37:24.972+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-08-25",{"id":95,"raw":96,"subject":80,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":18,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":23,"posted_date":106,"marcs_cms_no":107,"product_type":108,"closeout_date":19,"issuing_office":11,"recipient_name":109,"body_fetched_at":110,"delivery_method":111,"recipient_title":19,"reference_number":112,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},452,[97,98,99,11,80,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-30T04:00:00Z\">10\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025\">Owen Biosciences, Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-11\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Donald R. Owen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owen Biosciences, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7053 Revenue Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baton Rouge\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70809-4918\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-11\u003C\u002Fp>\u003Cp>October 30, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Owen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\u003C\u002Fp>\u003Cp>During the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\u003C\u002Fp>\u003Cp>In your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\u003C\u002Fli>\u003Cli>A detailed description of the method you establish to test for benzene in finished products prior to release.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\u003Cbr>o Validated stability-indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).\u003C\u002Fli>\u003Cli>Adequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\u003C\u002Fli>\u003Cli>Appropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Performance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failed Commitment to Recall Contaminated Drug Lot\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> communicated that it would voluntarily recall the product containing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled the product before it expired.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-11\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Donald R. Owen\n\nRecipient Title\n\nChief Executive Officer\n\nOwen Biosciences, Inc.\n\n7053 Revenue Drive\n\nBaton Rouge, LA 70809-4918\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-11\nOctober 30, 2025\nDear Dr. Owen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\nYour firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least (b)(4) lots of the (b)(4) 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of (b)(4) 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\nDuring the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the (b)(4) 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\nIn your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\nYour response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\nA detailed description of the method you establish to test for benzene in finished products prior to release.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\nYour response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\no Validated stability-indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\nAll procedures that describe these and other elements of your remediated stability program.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\nReview of production and control records to ensure completeness and accuracy (21 CFR 211.192).\nAdequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\nAppropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\nPerformance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\nIn your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\nYour response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\nFailed Commitment to Recall Contaminated Drug Lot\nFDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the (b)(4) Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, (b)(4), to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, (b)(4) communicated that it would voluntarily recall the product containing the (b)(4) Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor (b)(4) recalled the product before it expired.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\nFailure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Owen Biosciences, Inc.","owen-biosciences-inc-710275-10302025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025","2026-10-26T08:09:39.713108+00:00","2025-11-25","710275","Drugs Over-the-Counter Drugs","Dr. Donald R. Owen","2026-08-19T13:26:35.546+00:00","VIA Electronic Mail","320-26-11","2025-10-30",{"id":115,"raw":116,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":126,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":131,"closeout_date":19,"issuing_office":120,"recipient_name":132,"body_fetched_at":133,"delivery_method":111,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},975,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2025-04-01T04:00:00Z\">04\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-21T05:00:00Z\">02\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-science-llc-698114-02212025\">Next Science LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon E. Swanson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Next Science LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10550 Deerwood Park Blvd. Ste 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jacksonville\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32256\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@nextscience.com\"> (b)(6)@nextscience.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@nextscience.com\"> (b)(6)@nextscience.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 698114\u003C\u002Fp>\u003Cp>February 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Swanson:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Jacksonville, Florida on August 12 through September 5, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wound gels under the brand names SURGX® and BLASTX®, and wound irrigation solutions under the brand names XPERIENCE® and Bactisure®. These products include devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Lack of Marketing Authorization\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection and review of your firm’s website (https:\u002F\u002Fwww.nextscience.com\u002F) determined that the XPERIENCE®, BLASTX® and SURGX® products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the products, as described and marketed. These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b).\u003C\u002Fp>\u003Cp>The kind of information that your firm needs to submit in order to obtain approval or clearance for a device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Our office requests that your firm cease any activities that result in the misbranding or adulteration of the products.\u003C\u002Fp>\u003Cp>\u003Cu>XPERIENCE®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your XPERIENCE® product was cleared under K203835 as MIS Solution with the following indications for use: “MIS Solution is indicated for use in cleansing and removal of debris, including microorganisms, from wounds.” However, based on our inspection and review of your firm’s website, FDA is aware that you are marketing these products without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fxperience\u002F), including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“XPERIENCE rinses away debris and microorganisms from the surgical wound site.”\u003C\u002Fli>\u003Cli>“XPERIENCE does not have cytotoxic effects on osteoblasts. Cell viability and bone growth and healing were shown to be more favorable compared to 10% Betadine.”\u003C\u002Fli>\u003Cli>“XPERIENCE is cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics.”\u003C\u002Fli>\u003Cli>“XPERIENCE is compatible with most commonly used implants, including hydroxyapatite (HA) coated implants, and closure methods.”\u003C\u002Fli>\u003Cli>“XPERIENCE compatibility with surgical implants and closure methods (316 Stainless Steel, Chrome Alloy, Nylon Sutures, Polyethylene Sutures, Polyethylene, Polydimethylsulfoxide, Polyethylene Sutures, Polysulphone, Silk Sutures, Titanium, Tivanium and Hydroxyapatit Implants).”\u003C\u002Fli>\u003Cli>“5+ hours of ongoing, broad-spectrum efficacy.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and do not appear to be within the scope of the clearance issued under K203835. These claims also appear to constitute major changes or modifications in the intended use and could significantly affect the safety or effectiveness of the product that would require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by the Center for Drug Evaluation and Research (CDER) and subject to drug requirements. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>The agency previously expressed concerns with the use of XPERIENCE® in deep (surgical) wounds. However, you continue to market XPERIENCE® with the cited claims. For example:\u003C\u002Fp>\u003Cul>\u003Cli>On March 3, 2019, the FDA provided feedback in K203835, Additional Information Letter which stated that the intended use of your device is for use on breached or compromised skin. Any claims regarding the use of the XPERIENCE® product for deep wound cavities, fissures and wound pockets are not cleared under product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> to conduct an Investigational Device Exemption Study to expand the use of the XPERIENCE® product for the use in colorectal surgical wounds. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the FDA communicated our concern regarding the hemocompatibility of XPERIENCE® product, indicating that it is likely hemolytic. The FDA raised concern that hemocompatibility testing or scientific rationale is needed to evaluate the risk of using the XPERIENCE® product in surgical wounds. You have not provided any additional hemocompatibility report and have not been granted clearance for use of XPERIENCE® in deep (surgical) wounds.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BLASTX®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your BLASTX® product was cleared under K150792 as Next ScienceTM Wound Gel for Over-The-Counter Use with the following indications for use: “Next ScienceTM Wound Gel is indicated for the management of skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fblastx-wound-gel\u002F), including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“BLASTX® can be applied once daily for up to 30 days.”\u003C\u002Fli>\u003Cli>“BLASTX® has been shown to suppress inflammation and repair the skin’s barrier function.”\u003C\u002Fli>\u003Cli>“BLASTX® inactivates matrix Metalloproteases (MMPs), leading to stopping the cytokine cascade. Also, BLASTX® inactivates proteases production by the bacteria, which prevents tissue destruction and inflammation by the same mechanism.”\u003C\u002Fli>\u003Cli>“Lowers inflammation allowing transition to proliferative stage.”\u003C\u002Fli>\u003Cli>“BLASTX® Results in Fewer Days with Wounds, Fewer Amputations.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K150792. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>\u003Cu>SURGX®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your SURGX® product was cleared under K163188 as Next Science nonsterile wound gel for Prescription Use and with the following indications for use: “Next Science Wound Gel (Rx) is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“SURGX® Sterile Antimicrobial Gel as sterilized by gamma radiation for one time use.”\u003C\u002Fli>\u003Cli>“SURGX® is designed to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-encased bacteria within the gel. The proprietary, non-toxic formulation conforms to the postoperative wound to provide proven broad spectrum and sustained effectiveness for up to 5 days.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K163188. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>Additionally, your firm is currently marketing the XPERIENCE®, BLASTX® and SURGX® products as powered by XBIO® Technology. Our inspection and the review of your website (https:\u002F\u002Fwww.nextscience.com\u002F) indicates you are making the following claims for XBIO® Technology:\u003C\u002Fp>\u003Cul>\u003Cli>“Since 2012, Next Science has been developing revolutionary material science-based technology that is non-toxic with proven efficacy against bacteria and microorganisms. This technology is called XBIO®.”\u003C\u002Fli>\u003Cli>“XBIO™ Technology deconstructs biofilm by removing the metal ions holding it together.”\u003C\u002Fli>\u003Cli>“XBIO Technology takes an innovative approach to solving the problem of bacterial biofilms. The unique, non-toxic technology attacks and deconstructs the structure of the biofilm by removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm, making them more vulnerable to eradication. Bacteria that are enveloped within the XBIO Technology are then destroyed by the combination of a surfactant and high osmotic imbalance across the bacterial cell wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation, reducing the rate of reoccurrence by over 100X. Due to this unique mechanism of action there is no known resistance to XBIO Technology.”\u003C\u002Fli>\u003Cli>“XBIO gives physicians the transformational technology to help improve surgical outcomes for even their most at-risk patients.”\u003C\u002Fli>\u003Cli>“Through our anti-biofilm solutions, it is our purpose to help reduce infections and combat the rising problem of antimicrobial resistance.”\u003C\u002Fli>\u003Cli>“At Next Science, we are leading a paradigm shift with a unique approach to eradicating both biofilm bacteria and planktonic bacteria with our XBIO Technology. XBIO disrupts the biofilm’s extracellular polymeric substance and exposes the bacteria, once protected by the biofilm, leaving it more vulnerable to attack.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>From the review of your marketing material, you claim XBIO® Technology deconstructs biofilm by removing the metal ions holding biofilm together. The claims indicate that XBIO® Technology has effect on biofilm. XPERIENCE®, BLASTX® and SURGX® have not been evaluated for safety and effectiveness against biofilm. As communicated to you during the regulatory meeting held on May 5, 2022, the antimicrobial component found in your 510(k) cleared products are intended to function as a preservative that inhibits growth of microorganisms in the products and claims of effectiveness against biofilm are outside the clearance of XPERIENCE®, BLASTX® and SURGX®. Additionally, the claims found in our inspection and review of your website go beyond the types of claims appropriate for wound dressings and wound washes categorized under the FRO product code. Further, the claims raise jurisdictional issues, and if you intend to continue making such claims, we note that the products may be regulated by CDER and subject to drug requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection also revealed that these products are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and include testing of production units under actual or simulated use conditions, and include risk analysis where appropriate, as required by, 21 CFR 820.30(g). Specifically,\u003C\u002Fp>\u003Cp>a. Your firm did not provide evidence to demonstrate that the design of XPERIENCE® was validated for the uses claimed in the product labeling and marketing material. Design validation activities for XPERIENCE® (MIS Solution FDA 510(k) K203835) were conducted for cleansing and removal of debris, including microorganisms, from external topical wounds, but your firm markets the solution as “cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics,” areas that may pose a greater risk and potential adverse effects because of the access to blood vessels and bone. Your firm did not conduct additional blood compatibility studies when establishing the biocompatibility assessment of XPERIENCE® that would be relevant for the uses marketed by your firm. Without this information, there are outstanding questions related to hemolysis risks from the use of this product as marketed by your firm.\u003C\u002Fp>\u003Cp>b. Your firm did not present design validation studies to support the biofilm disruption mechanism of action currently promoted on your products’ labeling and marketing material. Specifically, your firm’s wound gels and irrigation solutions are labeled as “Powered by XBio®.” Your firm’s website explains that XBio® is a proprietary non-toxic technology platform that disrupts the biofilm’s EPS matrix by removing the metal ions holding it together without inhibiting new tissue growth, offers no known opportunity for bacteria resistance, and removes bacteria from the treated surface and defends against biofilm recurrence.\u003C\u002Fp>\u003Cp>c. Your firm failed to conduct design validation studies to support the website claim that SURGX® provides broad-spectrum efficacy and multi-log reduction within the gel for fungus \u003Cem>C. albicans and A. brasiliensis\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0029 in response to this observation and that the marketing materials were placed on your firm’s website by a marketing associate without going through the formal review and approval process. Your responses indicate that your firm did not intend to plan and promote these products for the uses described above. Your responses also indicate that you have corrected your website and that your firm will review all currently approved marketing materials to verify that there is supporting evidence for each claim and will remove any claims without such evidence. Your responses indicate that you have hired a Director of Marketing with experience related to medical devices. In addition, your responses stated that you have reopened your Risk Management Plan and initiated a comprehensive reevaluation of risk management activities in accordance with ISO 14971 to better evaluate potential harms associated with known conditions of use. Your responses also indicated that you will update your firm’s website to clearly differentiate the use of XBIO® Technology in non-FDA regulated applications. In addition, your January 15, 2025, response indicates that your firm has updated several applicable procedures. However, at this time, the adequacy of your corrections cannot be determined at this time. Your corrections are ongoing, and a follow-up inspection will verify the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\u003Cbr>Your firm’s procedure QOP-85-03, Customer Complaints, assigns responsibilities and provides a system and instructions for receiving and processing customer complaints relating to the product. This procedure was not adequately established in that:\u003C\u002Fp>\u003Cp>a. Information collected by your company from February 2022 through January 2023 regarding excessive bleeding caused by XPERIENCE® was not comprehensively evaluated to determine its relationship to the product and to understand the underlying potential mode or mechanism of failure when using the product on breast soft tissue. Specifically, your firm’s Medical Science Liaison Manager informed a clinical site on January 24, 2023, the following about the bleeding reports: “The fluid action coupled with the surfactant and citrates may loosen micro-clots. Moreover, a cleaner space than you usually see with just N\u002FS may make any extant bleeders more obvious. The general approach seems to be to simply slow down and allow those clots to stabilize before commencing aggressive irrigation.” There is no evidence that this information was further investigated to identify failure mode, risk of using the product on breast soft tissue, and any corrective action needed to preclude the bleeding and oozing adverse events.&nbsp;\u003C\u002Fp>\u003Cp>b. Complaints reporting several events under one report are entered in your complaint system as one complaint, limiting the extent of the investigation to be conducted for each individual case. Specifically, complaints received for XPERIENCE® reporting excessive bleeding did not include the nature and details of each individual case. In addition, data for complaint trending may be artificially lowered by grouping several events under one complaint, for example:\u003C\u002Fp>\u003Cp>i. Complaint # 00265- a surgeon reported three cases of bleeding he encountered at two different surgery centers.\u003Cbr>ii. Complaint # 00266- a surgeon reported two cases of increase in bleeding within the first five minutes after irrigating on capsulectomy cases.\u003Cbr>iii. Complaint # 00274- a surgeon reported three cases of oozing and bleeding and one case of hematoma.\u003Cbr>iv. Complaint # 00278- a surgeon reported three cases of diffuse bleeding and oozing.\u003Cbr>v. Complaint # 00299- a surgeon reported two cases of diffuse bleeding and one hematoma requiring drainage.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0033 and that you have updated your complaint handling module to ask whether new information has been received on a previously closed investigation that would warrant further investigation. Your responses also indicate that you have created a new procedure for Issue Impact Assessments QOP 85-05, and that training was conducted. In addition, your responses indicate that a retrospective review of complaints for all product families and new individual complaint events was opened. Also, your January 15, 2025, response indicates that your firm has updated QOP-82-01 to redefine the process, roles, and responsibilities for the act of reviewing publications, articles, literature reviews and opening complaint report records. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the adequacy of the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, per your Corrective and Preventive Action procedure QOP-85-004, a reported failure that may pose a significant patient safety risk and\u002For presents an upward trend of reported events are to be considered sources of corrective and preventive actions. Your firm did not follow this procedure for the XPERIENCE® bleeding complaints in that a CAPA was not opened after receiving at least twenty reports of excessive bleeding after using XPERIENCE® to rinse the breast pocket in breast surgery cases.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0036 and determined that the failure occurred because the relevant procedures did not properly trigger CAPA escalation. Your responses indicate that you have modified your procedures and conducted a retrospective review of complaints based on the updated procedures to determine if CAPAs need to be initiated for certain failures. Your January 15, 2025, response indicated that your firm concluded that no new issues required escalation to CAPA when compared against updated Customer Complaints procedure QOP-85-03. Your responses also indicate that you have developed a new procedure QOP-85-05 Issue Impact Assessment in order to have a documented determination for elevation to CAPA. Your responses indicate that the new procedure will require the Issue Impact Assessment be revisited (including CAPA determinations) when failure modes of a similar nature are detected. Your responses also indicate that you have developed a new work instruction that requires the reporting of trending of failure modes for adverse\u002Freportable\u002FIIA events. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s XPERIENCE® solution is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the product that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\u003C\u002Fp>\u003Cp>a. The information included for Complaint# 0299 reasonably suggests that a patient sustained an injury (hematoma) following the breast reduction surgery involving your firm’s XPERIENCE® solution, which required percutaneous aspiration. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on January 26, 2023, yet the corresponding MDR# 3012271775-2024-00002 was not received by the FDA until October 31, 2024, exceeding the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>b. The information included for Complaint# 0276 reasonably suggests that a patient sustained an injury (diffuse bleeding) on one breast pocket during a bilateral breast augmentation procedure involving the application of your firm’s XPERIENCE® solution, which required a saline wash and cauterization of the bleeding tissue to manage the situation. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on May 12, 2022, yet the corresponding MDR# 3012271775-2024-00004 was not received by the FDA until November 8, 2024, exceeding the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>We received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025. Your firm’s responses indicate that corrective actions have been taken to address this observation. These actions include streamlining the MDR reporting process by incorporating an MDR decision tree and conducting a retrospective review of XPERIENCE® complaints related to bleeding for MDR reportability. As a result, we acknowledge receipt of six newly identified MDRs. Additionally, your firm has completed a retrospective review of all complaints from the past three years and confirmed that no additional reportable events were identified. Please note that future FDA inspections or regulatory activities will assess the implementation and effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 698114 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJon E. Swanson\n\nRecipient Title\n\nCOO\n\nNext Science LLC\n\n10550 Deerwood Park Blvd. Ste 300\n\nJacksonville, FL 32256\n\nUnited States\n\n(b)(6)@nextscience.com\n\n(b)(6)@nextscience.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 698114\nFebruary 21, 2025\nDear Mr. Swanson:\nDuring an inspection of your firm located in Jacksonville, Florida on August 12 through September 5, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wound gels under the brand names SURGX® and BLASTX®, and wound irrigation solutions under the brand names XPERIENCE® and Bactisure®. These products include devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nLack of Marketing Authorization\nOur inspection and review of your firm’s website (https:\u002F\u002Fwww.nextscience.com\u002F) determined that the XPERIENCE®, BLASTX® and SURGX® products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the products, as described and marketed. These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b).\nThe kind of information that your firm needs to submit in order to obtain approval or clearance for a device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Our office requests that your firm cease any activities that result in the misbranding or adulteration of the products.\nXPERIENCE®\nYour XPERIENCE® product was cleared under K203835 as MIS Solution with the following indications for use: “MIS Solution is indicated for use in cleansing and removal of debris, including microorganisms, from wounds.” However, based on our inspection and review of your firm’s website, FDA is aware that you are marketing these products without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fxperience\u002F), including but not limited to:\n“XPERIENCE rinses away debris and microorganisms from the surgical wound site.”\n“XPERIENCE does not have cytotoxic effects on osteoblasts. Cell viability and bone growth and healing were shown to be more favorable compared to 10% Betadine.”\n“XPERIENCE is cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics.”\n“XPERIENCE is compatible with most commonly used implants, including hydroxyapatite (HA) coated implants, and closure methods.”\n“XPERIENCE compatibility with surgical implants and closure methods (316 Stainless Steel, Chrome Alloy, Nylon Sutures, Polyethylene Sutures, Polyethylene, Polydimethylsulfoxide, Polyethylene Sutures, Polysulphone, Silk Sutures, Titanium, Tivanium and Hydroxyapatit Implants).”\n“5+ hours of ongoing, broad-spectrum efficacy.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and do not appear to be within the scope of the clearance issued under K203835. These claims also appear to constitute major changes or modifications in the intended use and could significantly affect the safety or effectiveness of the product that would require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by the Center for Drug Evaluation and Research (CDER) and subject to drug requirements. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nThe agency previously expressed concerns with the use of XPERIENCE® in deep (surgical) wounds. However, you continue to market XPERIENCE® with the cited claims. For example:\nOn March 3, 2019, the FDA provided feedback in K203835, Additional Information Letter which stated that the intended use of your device is for use on breached or compromised skin. Any claims regarding the use of the XPERIENCE® product for deep wound cavities, fissures and wound pockets are not cleared under product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review.\n(b)(4) to conduct an Investigational Device Exemption Study to expand the use of the XPERIENCE® product for the use in colorectal surgical wounds. (b)(4), the FDA communicated our concern regarding the hemocompatibility of XPERIENCE® product, indicating that it is likely hemolytic. The FDA raised concern that hemocompatibility testing or scientific rationale is needed to evaluate the risk of using the XPERIENCE® product in surgical wounds. You have not provided any additional hemocompatibility report and have not been granted clearance for use of XPERIENCE® in deep (surgical) wounds.\nBLASTX®\nYour BLASTX® product was cleared under K150792 as Next ScienceTM Wound Gel for Over-The-Counter Use with the following indications for use: “Next ScienceTM Wound Gel is indicated for the management of skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fblastx-wound-gel\u002F), including but not limited to:\n“BLASTX® can be applied once daily for up to 30 days.”\n“BLASTX® has been shown to suppress inflammation and repair the skin’s barrier function.”\n“BLASTX® inactivates matrix Metalloproteases (MMPs), leading to stopping the cytokine cascade. Also, BLASTX® inactivates proteases production by the bacteria, which prevents tissue destruction and inflammation by the same mechanism.”\n“Lowers inflammation allowing transition to proliferative stage.”\n“BLASTX® Results in Fewer Days with Wounds, Fewer Amputations.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K150792. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nSURGX®\nYour SURGX® product was cleared under K163188 as Next Science nonsterile wound gel for Prescription Use and with the following indications for use: “Next Science Wound Gel (Rx) is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website, including but not limited to:\n“SURGX® Sterile Antimicrobial Gel as sterilized by gamma radiation for one time use.”\n“SURGX® is designed to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-encased bacteria within the gel. The proprietary, non-toxic formulation conforms to the postoperative wound to provide proven broad spectrum and sustained effectiveness for up to 5 days.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K163188. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nAdditionally, your firm is currently marketing the XPERIENCE®, BLASTX® and SURGX® products as powered by XBIO® Technology. Our inspection and the review of your website (https:\u002F\u002Fwww.nextscience.com\u002F) indicates you are making the following claims for XBIO® Technology:\n“Since 2012, Next Science has been developing revolutionary material science-based technology that is non-toxic with proven efficacy against bacteria and microorganisms. This technology is called XBIO®.”\n“XBIO™ Technology deconstructs biofilm by removing the metal ions holding it together.”\n“XBIO Technology takes an innovative approach to solving the problem of bacterial biofilms. The unique, non-toxic technology attacks and deconstructs the structure of the biofilm by removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm, making them more vulnerable to eradication. Bacteria that are enveloped within the XBIO Technology are then destroyed by the combination of a surfactant and high osmotic imbalance across the bacterial cell wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation, reducing the rate of reoccurrence by over 100X. Due to this unique mechanism of action there is no known resistance to XBIO Technology.”\n“XBIO gives physicians the transformational technology to help improve surgical outcomes for even their most at-risk patients.”\n“Through our anti-biofilm solutions, it is our purpose to help reduce infections and combat the rising problem of antimicrobial resistance.”\n“At Next Science, we are leading a paradigm shift with a unique approach to eradicating both biofilm bacteria and planktonic bacteria with our XBIO Technology. XBIO disrupts the biofilm’s extracellular polymeric substance and exposes the bacteria, once protected by the biofilm, leaving it more vulnerable to attack.”\nFrom the review of your marketing material, you claim XBIO® Technology deconstructs biofilm by removing the metal ions holding biofilm together. The claims indicate that XBIO® Technology has effect on biofilm. XPERIENCE®, BLASTX® and SURGX® have not been evaluated for safety and effectiveness against biofilm. As communicated to you during the regulatory meeting held on May 5, 2022, the antimicrobial component found in your 510(k) cleared products are intended to function as a preservative that inhibits growth of microorganisms in the products and claims of effectiveness against biofilm are outside the clearance of XPERIENCE®, BLASTX® and SURGX®. Additionally, the claims found in our inspection and review of your website go beyond the types of claims appropriate for wound dressings and wound washes categorized under the FRO product code. Further, the claims raise jurisdictional issues, and if you intend to continue making such claims, we note that the products may be regulated by CDER and subject to drug requirements.\nQuality System Regulation (QSR) Violations\nThis inspection also revealed that these products are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and include testing of production units under actual or simulated use conditions, and include risk analysis where appropriate, as required by, 21 CFR 820.30(g). Specifically,\na. Your firm did not provide evidence to demonstrate that the design of XPERIENCE® was validated for the uses claimed in the product labeling and marketing material. Design validation activities for XPERIENCE® (MIS Solution FDA 510(k) K203835) were conducted for cleansing and removal of debris, including microorganisms, from external topical wounds, but your firm markets the solution as “cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics,” areas that may pose a greater risk and potential adverse effects because of the access to blood vessels and bone. Your firm did not conduct additional blood compatibility studies when establishing the biocompatibility assessment of XPERIENCE® that would be relevant for the uses marketed by your firm. Without this information, there are outstanding questions related to hemolysis risks from the use of this product as marketed by your firm.\nb. Your firm did not present design validation studies to support the biofilm disruption mechanism of action currently promoted on your products’ labeling and marketing material. Specifically, your firm’s wound gels and irrigation solutions are labeled as “Powered by XBio®.” Your firm’s website explains that XBio® is a proprietary non-toxic technology platform that disrupts the biofilm’s EPS matrix by removing the metal ions holding it together without inhibiting new tissue growth, offers no known opportunity for bacteria resistance, and removes bacteria from the treated surface and defends against biofilm recurrence.\nc. Your firm failed to conduct design validation studies to support the website claim that SURGX® provides broad-spectrum efficacy and multi-log reduction within the gel for fungus C. albicans and A. brasiliensis.\nYour responses indicate that you have opened CAPA 0029 in response to this observation and that the marketing materials were placed on your firm’s website by a marketing associate without going through the formal review and approval process. Your responses indicate that your firm did not intend to plan and promote these products for the uses described above. Your responses also indicate that you have corrected your website and that your firm will review all currently approved marketing materials to verify that there is supporting evidence for each claim and will remove any claims without such evidence. Your responses indicate that you have hired a Director of Marketing with experience related to medical devices. In addition, your responses stated that you have reopened your Risk Management Plan and initiated a comprehensive reevaluation of risk management activities in accordance with ISO 14971 to better evaluate potential harms associated with known conditions of use. Your responses also indicated that you will update your firm’s website to clearly differentiate the use of XBIO® Technology in non-FDA regulated applications. In addition, your January 15, 2025, response indicates that your firm has updated several applicable procedures. However, at this time, the adequacy of your corrections cannot be determined at this time. Your corrections are ongoing, and a follow-up inspection will verify the effectiveness of your corrective actions.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\nYour firm’s procedure QOP-85-03, Customer Complaints, assigns responsibilities and provides a system and instructions for receiving and processing customer complaints relating to the product. This procedure was not adequately established in that:\na. Information collected by your company from February 2022 through January 2023 regarding excessive bleeding caused by XPERIENCE® was not comprehensively evaluated to determine its relationship to the product and to understand the underlying potential mode or mechanism of failure when using the product on breast soft tissue. Specifically, your firm’s Medical Science Liaison Manager informed a clinical site on January 24, 2023, the following about the bleeding reports: “The fluid action coupled with the surfactant and citrates may loosen micro-clots. Moreover, a cleaner space than you usually see with just N\u002FS may make any extant bleeders more obvious. The general approach seems to be to simply slow down and allow those clots to stabilize before commencing aggressive irrigation.” There is no evidence that this information was further investigated to identify failure mode, risk of using the product on breast soft tissue, and any corrective action needed to preclude the bleeding and oozing adverse events.\nb. Complaints reporting several events under one report are entered in your complaint system as one complaint, limiting the extent of the investigation to be conducted for each individual case. Specifically, complaints received for XPERIENCE® reporting excessive bleeding did not include the nature and details of each individual case. In addition, data for complaint trending may be artificially lowered by grouping several events under one complaint, for example:\ni. Complaint # 00265- a surgeon reported three cases of bleeding he encountered at two different surgery centers.\nii. Complaint # 00266- a surgeon reported two cases of increase in bleeding within the first five minutes after irrigating on capsulectomy cases.\niii. Complaint # 00274- a surgeon reported three cases of oozing and bleeding and one case of hematoma.\niv. Complaint # 00278- a surgeon reported three cases of diffuse bleeding and oozing.\nv. Complaint # 00299- a surgeon reported two cases of diffuse bleeding and one hematoma requiring drainage.\nYour responses indicate that you have opened CAPA 0033 and that you have updated your complaint handling module to ask whether new information has been received on a previously closed investigation that would warrant further investigation. Your responses also indicate that you have created a new procedure for Issue Impact Assessments QOP 85-05, and that training was conducted. In addition, your responses indicate that a retrospective review of complaints for all product families and new individual complaint events was opened. Also, your January 15, 2025, response indicates that your firm has updated QOP-82-01 to redefine the process, roles, and responsibilities for the act of reviewing publications, articles, literature reviews and opening complaint report records. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the adequacy of the implementation and the effectiveness of your corrective actions.\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, per your Corrective and Preventive Action procedure QOP-85-004, a reported failure that may pose a significant patient safety risk and\u002For presents an upward trend of reported events are to be considered sources of corrective and preventive actions. Your firm did not follow this procedure for the XPERIENCE® bleeding complaints in that a CAPA was not opened after receiving at least twenty reports of excessive bleeding after using XPERIENCE® to rinse the breast pocket in breast surgery cases.\nYour responses indicate that you have opened CAPA 0036 and determined that the failure occurred because the relevant procedures did not properly trigger CAPA escalation. Your responses indicate that you have modified your procedures and conducted a retrospective review of complaints based on the updated procedures to determine if CAPAs need to be initiated for certain failures. Your January 15, 2025, response indicated that your firm concluded that no new issues required escalation to CAPA when compared against updated Customer Complaints procedure QOP-85-03. Your responses also indicate that you have developed a new procedure QOP-85-05 Issue Impact Assessment in order to have a documented determination for elevation to CAPA. Your responses indicate that the new procedure will require the Issue Impact Assessment be revisited (including CAPA determinations) when failure modes of a similar nature are detected. Your responses also indicate that you have developed a new work instruction that requires the reporting of trending of failure modes for adverse\u002Freportable\u002FIIA events. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s XPERIENCE® solution is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the product that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\na. The information included for Complaint# 0299 reasonably suggests that a patient sustained an injury (hematoma) following the breast reduction surgery involving your firm’s XPERIENCE® solution, which required percutaneous aspiration. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on January 26, 2023, yet the corresponding MDR# 3012271775-2024-00002 was not received by the FDA until October 31, 2024, exceeding the required 30-calendar-day reporting timeframe.\nb. The information included for Complaint# 0276 reasonably suggests that a patient sustained an injury (diffuse bleeding) on one breast pocket during a bilateral breast augmentation procedure involving the application of your firm’s XPERIENCE® solution, which required a saline wash and cauterization of the bleeding tissue to manage the situation. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on May 12, 2022, yet the corresponding MDR# 3012271775-2024-00004 was not received by the FDA until November 8, 2024, exceeding the required 30-calendar-day reporting timeframe.\nWe received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025. Your firm’s responses indicate that corrective actions have been taken to address this observation. These actions include streamlining the MDR reporting process by incorporating an MDR decision tree and conducting a retrospective review of XPERIENCE® complaints related to bleeding for MDR reportability. As a result, we acknowledge receipt of six newly identified MDRs. Additionally, your firm has completed a retrospective review of all complaints from the past three years and confirmed that no additional reportable events were identified. Please note that future FDA inspections or regulatory activities will assess the implementation and effectiveness of your corrective actions.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 698114 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Next Science LLC","next-science-llc-698114-02212025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-science-llc-698114-02212025","2026-10-26T08:09:33.109663+00:00","2025-04-01","698114","Medical Devices","Jon E. Swanson","2026-08-19T16:53:57.644+00:00","2025-02-21",{"id":136,"raw":137,"subject":141,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":18,"fei_number":19,"letter_url":146,"updated_at":147,"action_type":22,"case_status":23,"posted_date":148,"marcs_cms_no":149,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":150,"body_fetched_at":151,"delivery_method":71,"recipient_title":19,"reference_number":152,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},365,[138,139,140,11,141,13,13,13],"\u003Ctime datetime=\"2026-01-20T05:00:00Z\">01\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodrome-sciences-usa-llc-717959-01082026\">Prodrome Sciences USA, LLC\u003C\u002Fa>","Sponsor\u002FUnapproved Misbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-01-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dayan B. Goodenowe, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Prodrome Sciences USA, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>27518 Via Industria\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Temecula\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92590\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Goodenowe:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between December 17, 2024, and January 10, 2025. The investigator representing FDA reviewed the role of Prodrome Sciences USA, LLC (Prodrome Sciences) as the sponsor of a clinical investigation (Protocol Pro‐040‐Plasm‐01, “ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline”) of the investigational drug ProdromeNeuro™ Oil (Omega-3 Plasmalogens).\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written responses to the Form FDA 483, dated January 23 and January 31, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated January 23 and January 31, 2025, it appears that Prodrome Sciences did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Prodrome Sciences failed to comply with these requirements. Specifically, Prodrome Sciences initiated and conducted Protocol Pro‐040‐Plasm‐01, a clinical investigation of the investigational drug ProdromeNeuro™ Oil, subject to section 505 of the FD&amp;C Act [21 U.S.C. 355], without submitting and having in effect an IND.\u003C\u002Fp>\u003Cp>In Prodrome Sciences’ January 31, 2025, written response to the Form FDA 483, you indicated that the objective of Protocol Pro‐040‐Plasm‐01 was to evaluate the safety and tolerability of ProdromeNeuro™ Oil as a nutritional supplement. Additionally, during the inspection you stated that the investigational product, ProdromeNeuro™ Oil, is a blend of naturally occurring alkylglycerols composed of docosahexaenoic acid (DHA) [22:6], docosapentaenoic acid (DPA) [22:5], and eicosapentaenoic acid (EPA) [20:5] fatty acids. You further stated that these dietary alkylglycerols are found naturally in shark liver oil, which makes ProdromeNeuro™ Oil a dietary supplement that does not require an IND.\u003C\u002Fp>\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that ProdromeNeuro™ Oil was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol Pro‐040‐Plasm‐01. Therefore, Prodrome Sciences was required to submit an IND before conducting the clinical investigation.\u003C\u002Fp>\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” Although Protocol Pro-040-Plasm-01 stated that the primary objective was to evaluate the safety and tolerability of ProdromeNeuro™ Oil in subjects with age-related cognitive decline, the inclusion criteria for the study expressly included subjects with mild to moderate dementia, and the protocol stated that one outcome of the study was to provide subjects with some improvement in their cognitive status. The outcome assessments for Protocol Pro-040-Plasm-01 included various validated neurocognitive assessments at baseline, and at follow-up visits at months one through five after baseline. These outcome assessments included the Standardized 25-foot Timed Gait Test, the Nine Hole Pegboard Test, the Montreal Cognitive Assessment, and the Quick Dementia Rating Scale, all of which are instruments used to assess neurocognitive status. Therefore, Protocol Pro-040-Plasm-01 collected study data to assess the effect of ProdromeNeuro™ Oil on cognitive status – as measured by changes in gait and changes in the severity of dementia, as determined by cognitive and functional abilities – of individuals with mild to moderate dementia.\u003C\u002Fp>\u003Cp>Whether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol Pro-040-Plasm-01, the investigational product, ProdromeNeuro™ Oil, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&amp;C Act, because ProdromeNeuro™ Oil was studied for use in the treatment of mild to moderate dementia.\u003C\u002Fp>\u003Cp>Thus, before initiating the clinical investigation of ProdromeNeuro™ Oil conducted under Protocol Pro-040-Plasm-01, under 21 CFR 312.40, Prodrome Sciences was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that Prodrome Sciences failed to submit an IND before conducting Protocol Pro-040-Plasm-01, in which 29 human subjects were enrolled and received investigational drug between July 2020 and March 2021.\u003C\u002Fp>\u003Cp>In your January 23 and January 31, 2025, written responses, you stated that Prodrome Sciences has hired a consulting partner to assist with remediation and resolution of the Form FDA 483 observation, and to provide ongoing FDA compliance support.\u003C\u002Fp>\u003Cp>In your written responses, you also outlined a corrective and preventive action plan that includes the following: (1) a comprehensive review of standard operating procedures and training programs to identify and address gaps; (2) employee training overseen by your consulting partner on the FDA requirements for dietary supplements, and the differences between clinical studies involving dietary supplements and clinical studies involving investigational drugs; and (3) regular audits conducted by your consulting partner to monitor the effectiveness of these actions.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions you have taken and plan to take, your written response is inadequate because your corrective action plan did not include sufficient information to address how Prodrome Sciences, as a sponsor, will prevent similar violations in the future. For example, your response does not include sufficient details on how Prodrome Sciences, as a sponsor, will determine whether IND regulations apply to future clinical investigations of products regulated by FDA, as required under 21 CFR part 312.2(a). Additionally, your corrective and preventive action plan does not include sufficient details about developing and implementing procedures to comply with IND regulations, if Prodrome Sciences should decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Prodrome Sciences will comply with IND regulations in the future.\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible to comply with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation; and it is Prodrome Sciences’ responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Prodrome Sciences’ failure to submit, and to have in effect, an IND before initiating Protocol Pro-040-Plasm-01 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Protocol Pro-040-Plasm-01 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated during the inspection and in your January 31, 2025, written response, ProdromeNeuro™ Oil is marketed as a dietary supplement, not as a drug product.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-01-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDayan B. Goodenowe, Ph.D.\n\nRecipient Title\n\nCEO\n\nProdrome Sciences USA, LLC\n\n27518 Via Industria\n\nTemecula, CA 92590\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDear Dr. Goodenowe:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between December 17, 2024, and January 10, 2025. The investigator representing FDA reviewed the role of Prodrome Sciences USA, LLC (Prodrome Sciences) as the sponsor of a clinical investigation (Protocol Pro‐040‐Plasm‐01, “ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline”) of the investigational drug ProdromeNeuro™ Oil (Omega-3 Plasmalogens).\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written responses to the Form FDA 483, dated January 23 and January 31, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated January 23 and January 31, 2025, it appears that Prodrome Sciences did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\nYou failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\nFDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.1 Prodrome Sciences failed to comply with these requirements. Specifically, Prodrome Sciences initiated and conducted Protocol Pro‐040‐Plasm‐01, a clinical investigation of the investigational drug ProdromeNeuro™ Oil, subject to section 505 of the FD&C Act [21 U.S.C. 355], without submitting and having in effect an IND.\nIn Prodrome Sciences’ January 31, 2025, written response to the Form FDA 483, you indicated that the objective of Protocol Pro‐040‐Plasm‐01 was to evaluate the safety and tolerability of ProdromeNeuro™ Oil as a nutritional supplement. Additionally, during the inspection you stated that the investigational product, ProdromeNeuro™ Oil, is a blend of naturally occurring alkylglycerols composed of docosahexaenoic acid (DHA) [22:6], docosapentaenoic acid (DPA) [22:5], and eicosapentaenoic acid (EPA) [20:5] fatty acids. You further stated that these dietary alkylglycerols are found naturally in shark liver oil, which makes ProdromeNeuro™ Oil a dietary supplement that does not require an IND.\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that ProdromeNeuro™ Oil was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol Pro‐040‐Plasm‐01. Therefore, Prodrome Sciences was required to submit an IND before conducting the clinical investigation.\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” Although Protocol Pro-040-Plasm-01 stated that the primary objective was to evaluate the safety and tolerability of ProdromeNeuro™ Oil in subjects with age-related cognitive decline, the inclusion criteria for the study expressly included subjects with mild to moderate dementia, and the protocol stated that one outcome of the study was to provide subjects with some improvement in their cognitive status. The outcome assessments for Protocol Pro-040-Plasm-01 included various validated neurocognitive assessments at baseline, and at follow-up visits at months one through five after baseline. These outcome assessments included the Standardized 25-foot Timed Gait Test, the Nine Hole Pegboard Test, the Montreal Cognitive Assessment, and the Quick Dementia Rating Scale, all of which are instruments used to assess neurocognitive status. Therefore, Protocol Pro-040-Plasm-01 collected study data to assess the effect of ProdromeNeuro™ Oil on cognitive status – as measured by changes in gait and changes in the severity of dementia, as determined by cognitive and functional abilities – of individuals with mild to moderate dementia.\nWhether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol Pro-040-Plasm-01, the investigational product, ProdromeNeuro™ Oil, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&C Act, because ProdromeNeuro™ Oil was studied for use in the treatment of mild to moderate dementia.\nThus, before initiating the clinical investigation of ProdromeNeuro™ Oil conducted under Protocol Pro-040-Plasm-01, under 21 CFR 312.40, Prodrome Sciences was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that Prodrome Sciences failed to submit an IND before conducting Protocol Pro-040-Plasm-01, in which 29 human subjects were enrolled and received investigational drug between July 2020 and March 2021.\nIn your January 23 and January 31, 2025, written responses, you stated that Prodrome Sciences has hired a consulting partner to assist with remediation and resolution of the Form FDA 483 observation, and to provide ongoing FDA compliance support.\nIn your written responses, you also outlined a corrective and preventive action plan that includes the following: (1) a comprehensive review of standard operating procedures and training programs to identify and address gaps; (2) employee training overseen by your consulting partner on the FDA requirements for dietary supplements, and the differences between clinical studies involving dietary supplements and clinical studies involving investigational drugs; and (3) regular audits conducted by your consulting partner to monitor the effectiveness of these actions.\nWhile we acknowledge the corrective and preventive actions you have taken and plan to take, your written response is inadequate because your corrective action plan did not include sufficient information to address how Prodrome Sciences, as a sponsor, will prevent similar violations in the future. For example, your response does not include sufficient details on how Prodrome Sciences, as a sponsor, will determine whether IND regulations apply to future clinical investigations of products regulated by FDA, as required under 21 CFR part 312.2(a). Additionally, your corrective and preventive action plan does not include sufficient details about developing and implementing procedures to comply with IND regulations, if Prodrome Sciences should decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Prodrome Sciences will comply with IND regulations in the future.\nAs a sponsor, you are responsible to comply with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation; and it is Prodrome Sciences’ responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Prodrome Sciences’ failure to submit, and to have in effect, an IND before initiating Protocol Pro-040-Plasm-01 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\nYour written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n\u002FS\u002F\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________________\n1 Protocol Pro-040-Plasm-01 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated during the inspection and in your January 31, 2025, written response, ProdromeNeuro™ Oil is marketed as a dietary supplement, not as a drug product.","Prodrome Sciences USA, LLC","prodrome-sciences-usa-llc-717959-01082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodrome-sciences-usa-llc-717959-01082026","2026-10-26T08:09:44.574717+00:00","2026-01-20","717959","Dayan B. Goodenowe, Ph.D.","2026-08-19T07:17:30.103+00:00","26-HFD-45-01-01","2026-01-08",{"id":155,"raw":156,"subject":80,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":126,"fei_number":19,"letter_url":165,"updated_at":166,"action_type":22,"case_status":23,"posted_date":167,"marcs_cms_no":168,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":169,"body_fetched_at":170,"delivery_method":28,"recipient_title":19,"reference_number":171,"action_taken_date":172,"medical_device_id":19,"response_letter_date":19},796,[157,158,159,11,160,13,13,13],"\u003Ctime datetime=\"2025-07-03T04:00:00Z\">07\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-02T04:00:00Z\">07\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexela-pharma-sciences-llc-709859-07022025\">Exela Pharma Sciences, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-88\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Phanesh Koneru, PhD, LL.M.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Exela Pharma Sciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1245 Blowing Rock Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lenoir\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>28645-3618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-88\u003C\u002Fp>\u003Cp>July 2, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Koneru:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Exela Pharma Sciences, FEI 3008563008, at 1245 Blowing Rock Blvd, Lenoir, NC 28645, from November 4, 2024, to November 15, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals based on observations made at that time and our subsequent analysis. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your December 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>I. Drug Manufacturing Operations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your facility is registered under section 510 of the FD&amp;C ACT and manufactures multiple drug products pursuant to New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA).\u003C\u002Fp>\u003Cp>This section summarizes significant violations of CGMP regulations for finished pharmaceuticals you manufacture. See 21 CFR parts 210 and 211.\u003C\u002Fp>\u003Cp>FDA investigators documented CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. The violations include, for example:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. You invalidated, without an adequate root cause investigation, failing growth promotion results, which are used to determine suitability of media used for sterility testing of finished drug products. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was used in the release sterility testing of multiple application drug products, including, but not limited to, ephedrine sulfate injection 5 mg\u002FmL, potassium acetate injection 2 mEq\u002FmL, folic acid injection 5 mg\u002FmL, tranexamic acid injection 10 mg\u002FmL, cupric chloride injection 1 mg\u002FmL, glycopyrrolate injection 0.2 mg\u002FmL, sodium bicarbonate injection 1 mEq\u002FmL, nicardipine HCl 2.5 mg\u002FmL, fentanyl citrate injection 50 mcg\u002FmL, sodium nitroprusside injection 0.2 mg\u002FmL, streptomycin injection, ibuprofen lysine injection 10 mg\u002FmL, caffeine citrate injection 20 mg\u002FmL, palonosetron HCl 0.125 mg\u002FmL, pentamidine isethionate for inhalation, zinc chloride injection, and argatroban injection 100 mg\u002FmL, despite growth promotion testing failing twice and passing on a third test. Your investigation concluded there was no product impact because retesting of the media ultimately achieved passing results. Your investigation documented human performance as the cause of the failing testing events for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> other media lots; however, no specific human error was identified.\u003C\u002Fp>\u003Cp>Your initial response acknowledged the investigation did not adequately document the evidence supporting the identified root cause despite the availability of test data. You also committed to revise SOP-000147 to require investigations for any confirmed or unconfirmed growth promotion failure and you plan to hire a third-party consultant to perform a retrospective review of investigations and train personnel.\u003C\u002Fp>\u003Cp>Your initial response was inadequate. Your initial response did not include a copy of your revised procedure for “Quality Control Testing of Microbiological Test Media”, SOP-000147, to support your commitments to require investigations for all test failures and associated training for all analysts. Additionally, your investigation does not include a review of all failing growth promotion media for all application drug product batches tested using these media lots. Your initial response also did not provide protocols for your proposed retrospective assessments.\u003C\u002Fp>\u003Cp>b. You invalidated, without an adequate root cause investigation, out-of-specification (OOS) results for sub-visible particulate matter testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of sodium bicarbonate injection when one of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials failed. Your investigation documented that \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed in the sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the failing vial, and the analyst was instructed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> the line to clear the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. When a retest of the vial did not confirm the original results, you prepared new vials which gave passing results. Although you identified the root cause as related to human error, no corrective action or training was implemented to prevent recurrence.\u003C\u002Fp>\u003Cp>Your initial response stated the root cause was due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> and acknowledged that the analyst failed to follow the procedure. You stated you will revise your testing procedure “to include \u003Cstrong>(b)(4)\u003C\u002Fstrong> requirement for product that contains \u003Cstrong>(b)(4)\u003C\u002Fstrong>” … “to address any future human errors related to the dissipation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for particulate matter analysis.”\u003C\u002Fp>\u003Cp>Your initial response was inadequate. Although your response indicates there were two quality events (QE) in a 10-day span due to OOS (high) particulate matter counts, your investigation determined there was no “formal” trend and no corrective action was needed. The second QE-000622 included “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the analyst to understand the importance of allowing time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your initial response did not include a copy of your revised procedure, QCMET-000074, “Determination of Particulate Matter in Finished Drug Products,” and documentation to show all analysts who perform this test method have been retrained to prevent recurrence.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequately scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to accurately document microbiology testing results. In addition, test results are not verified by a second person for accuracy. Specifically, on November 6, 2024, your analyst recorded fewer colony forming units for active air environmental monitoring samples than what was observed by our investigator during the examination. An independent review of the plate count by a second analyst to assure accuracy of the data was not conducted.\u003C\u002Fp>\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the quality unit’s ability to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\u003Cp>Your initial response acknowledged “a secondary, contemporaneous verification of environmental monitoring samples is fundamental to maintaining the integrity of such data.” You also committed to revise your procedures to require a second person review for all tests and to perform a retrospective review of “microbiology laboratory activities to identify activities that are not currently recorded electronically or contemporaneously.”\u003C\u002Fp>\u003Cp>Your initial response was inadequate because it failed to address the misread plate counts observed during the inspection for viable air and identify corrective and preventative actions for this failure. Moreover, your response lacks an assessment of potential data integrity concerns associated with one-person verification.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>II. Outsourcing Facility Operations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You also registered your facility with FDA as an outsourcing facility under section 503B of the FD&amp;C Act [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on June 6, 2014, initially, and most recently on January 1, 2024. Your facility deregistered as an outsourcing facility on December 20, 2024. We acknowledge your stated intent to discontinue production and distribution of 503B products effective January 31, 2025. As described below, the violations described in this letter are based on the observations in the most recent inspection and subsequent analysis, and they would continue to apply should you resume producing drug products intended to meet the conditions of section 503B.\u003C\u002Fp>\u003Cp>During the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FD&amp;C Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FD&amp;C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&amp;C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FD&amp;C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&amp;C Act are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FD&amp;C Act [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FD&amp;C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FD&amp;C Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigators noted CGMP violations at your outsourcing facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\u003Cp>2. Your firm failed to conduct laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.167(a)).\u003C\u002Fp>\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>4. Laboratory records are deficient in that they do not include the initials and signature of the second person reviewing the record for accuracy (21 CFR 211.194(a)(8)).\u003C\u002Fp>\u003Cp>5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fp>\u003Cp>6. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\u003C\u002Fp>\u003Cp>7. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s current thinking regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We acknowledge that your facility deregistered as an outsourcing facility on December 20, 2024.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>Regarding your firm’s process validation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles used to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilize Sodium Chloride Injection 0.9% USP in 500mL IV bags being performed using \u003Cstrong>(b)(4)\u003C\u002Fstrong> and not the drug product, you state that notwithstanding your discussion regarding this observation, “Exela understands the Agency’s position in raising this issue. If the 503B program continues, pending further discussions with the Agency, Exela intends to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles for 0.9% Sodium Chloride Injection, 1000 mL IV bags using the actual product. This will be supplemented by sterility testing at release.” We acknowledge this commitment to performing the validations and sterility testing. If you decide to produce drugs intended or expected to be sterile in accordance with 503B, you would be subject to CGMPs, including conducting process validations for all drug products prior to their production and distribution.\u003C\u002Fp>\u003Cp>Additionally, some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> to release sterility testing of Sodium Acetate Injection (in vials). However, two tests of lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> were invalidated and the third test was passed without scientific rationale. Your firm's investigation, QE-000487, states human performance was determined to be the root cause of the failed testing events. However, your firm did not document any specific human error identified when testing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> media. Three other lots of test media (\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were documented in your firm's investigation, QE-000487, as failing initial GPT and passing retest, however, no root cause for these test failures were documented.\u003C\u002Fp>\u003Cp>In your responses, you state there was no impact to finished drug product since the observation resulted from human error rather than the media itself, however, you did not provide in your response evidence as to how you determined human error was the sole reason for the failed tests. In addition, your responses did not identify the source of the human error, or identify any improper techniques utilized by analyst(s) during the testing.\u003C\u002Fp>\u003Cp>2. You failed to perform contemporaneous two-person checks during the reading of environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates and subsequent data entry of the results in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> software system. A single analyst reads environmental plate counts, takes pictures only of the positive counts, and then enters results in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software system. The Quality Control (QC) personnel later review and verify the results in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software system. There is no assurance the analyst read plate counts accurately or entered data in the software system accurately. On November 6, 2024, an FDA investigator observed miscounted plates with discrepancies when compared to the analyst’s count which were later corrected by the analyst.\u003C\u002Fp>\u003Cp>In your responses, you state that section 6.8.7.5 of your SOP-000189 “Use, Preparation, and Storage of QC – Microbiology Laboratory Media” has been revised. However, the revision does not clearly define when or how the second verifier will “…visually verify the presence or absence of microbiological growth….” Nor does the SOP address required timeframes as to when the second person will verify growth and ensure data is entered timely and correctly in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. As written, the SOP fails to ensure contemporaneous QC review of plate counts and data accuracy.\u003C\u002Fp>\u003Cp>3. Regarding your failing to have stability data to support a six-month expiration date for Sodium Chloride 0.9%, USP packaged in 500 mL polypropylene IV bags from a batch size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” line in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> building, your firm was not adhering to your SOP-QA-000064, “Stability Policy and Guidelines for Establishing Expiration Date or Beyond Use Date of 503B Product.” Section 6.1.5, of the SOP, states stability protocols will be established, and studies will be conducted for variations of 503B products. Your response states you have discontinued the 503B program and are no longer 503B registered. If you decide to produce drugs in accordance with 503B, the establishment of stability protocols are expected to be completed and studies to be in process before producing and distributing finished drug product.\u003C\u002Fp>\u003Cp>We note that you refer to the “Temporary Policies for Compounding Certain Parenteral Drug Products Guidance for Industry, October 2024” in your response. It appears that your FDA 483 response may incorrectly describe some of the conditions discussed in this guidance. Should you resume production, in accordance with 503B, with the intent to qualify for the temporary policies described in this guidance, you should review it, particularly the conditions including using a default BUD of not more than 28 days at room temperature and not more than 42 days refrigerated when a sterility test has not been completed before release; the initiation of limited stability testing once the aggregate batch size of the product is expected to exceed 5,000 units; and initiation of CCIT with the first batch.\u003C\u002Fp>\u003Cp>4. Regarding your firm’s visual inspection program, you committed to developing improvements to your existing visual inspection program, however, no information was provided of what you will do in the meantime before all the corrections have been made, evaluated, and revised, if needed, along with training. In addition, we have the following concerns with your planned corrections:\u003C\u002Fp>\u003Cul>\u003Cli>You state that your defect rates will be based on \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Visual Inspection of Medicinal Products for Parenteral Use standards\u003C\u002Fem>. You did not provide any details explaining your rationale for using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards.\u003C\u002Fli>\u003Cli>Deficiencies on the risk assessment of your visual inspection program and process.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>i. Your risk assessment explains \u003Cstrong>(b)(4)\u003C\u002Fstrong> defects (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) were not physically represented in the library of defects and concluded that they did not impact the integrity of the unit and, therefore, would have no impact on the patient. However, no information was provided as to why these \u003Cstrong>(b)(4)\u003C\u002Fstrong> defects would not impact the integrity of the unit or why the damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> was classified as a major defect rather than critical.\u003C\u002Fp>\u003Cp>ii. Your risk assessment stated, “From the risk ratings and review of other data, although the test sets did not include an example of each defect type identified in SOP-000266, this assessment provides confidence that the robust training program provided adequate training on the identification of defects through the training hours in conjunction with the visual aid of defects….” This assessment appears flawed as it is based on test sets not including an example of each defect type and based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> data rather than data collected during the visual inspection phase.\u003C\u002Fp>\u003Cp>iii. It is not apparent if your risk assessment considered whether particulates could be inherent, intrinsic, or extrinsic in nature. It is not clear whether you have established defect \u003Cstrong>(b)(4)\u003C\u002Fstrong> with known inherent, intrinsic, or extrinsic defects for particulates. Therefore, it is not known whether visual inspectors can identify those defects during visual inspection. Furthermore, you are classifying all particulates as major defects, and your rationale for this classification is not provided.\u003C\u002Fp>\u003Cul>\u003Cli>Your training or requalification time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> periods does not reflect actual visual inspection conditions as documented in your batch record visual inspection worksheets.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FD&amp;C Act. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)]\u003C\u002Fp>\u003Cp>FDA strongly recommends that if you decide to resume compounding and distribution of sterile drugs your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>III. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>If you decide to resume operations under section 503B of the FD&amp;C Act, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>As part of your response, please verify in writing your continuing intention to not resume operations under section 503B of the FD&amp;C Act. If you intend to resume such operations in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. In addition to taking appropriate corrective actions, you should also notify us fifteen (15) working days prior to resuming production of drugs under section 503B of the FD&amp;C Act in the future by contacting compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008563008 and ATTN: Erika V. Butler.\u003C\u002Fp>\u003Cp>We also recommend that, after you submit your response, you submit a Post-Warning Letter Meeting\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> request to: FDA-GDUFAIII-PostWarningLetterandReinspectionRequests@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans. Please see the Guidance for Industry “Post-Warning Letter Meetings Under GDUFA” for more information: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F171785\u002Fdownload\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-88\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nPhanesh Koneru, PhD, LL.M.\n\nRecipient Title\n\nPresident and CEO\n\nExela Pharma Sciences, LLC\n\n1245 Blowing Rock Blvd\n\nLenoir, NC 28645-3618\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-88\nJuly 2, 2025\nDear Dr. Koneru:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Exela Pharma Sciences, FEI 3008563008, at 1245 Blowing Rock Blvd, Lenoir, NC 28645, from November 4, 2024, to November 15, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals based on observations made at that time and our subsequent analysis. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your December 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nI. Drug Manufacturing Operations\nYour facility is registered under section 510 of the FD&C ACT and manufactures multiple drug products pursuant to New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA).\nThis section summarizes significant violations of CGMP regulations for finished pharmaceuticals you manufacture. See 21 CFR parts 210 and 211.\nFDA investigators documented CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\na. You invalidated, without an adequate root cause investigation, failing growth promotion results, which are used to determine suitability of media used for sterility testing of finished drug products. (b)(4), lot (b)(4), was used in the release sterility testing of multiple application drug products, including, but not limited to, ephedrine sulfate injection 5 mg\u002FmL, potassium acetate injection 2 mEq\u002FmL, folic acid injection 5 mg\u002FmL, tranexamic acid injection 10 mg\u002FmL, cupric chloride injection 1 mg\u002FmL, glycopyrrolate injection 0.2 mg\u002FmL, sodium bicarbonate injection 1 mEq\u002FmL, nicardipine HCl 2.5 mg\u002FmL, fentanyl citrate injection 50 mcg\u002FmL, sodium nitroprusside injection 0.2 mg\u002FmL, streptomycin injection, ibuprofen lysine injection 10 mg\u002FmL, caffeine citrate injection 20 mg\u002FmL, palonosetron HCl 0.125 mg\u002FmL, pentamidine isethionate for inhalation, zinc chloride injection, and argatroban injection 100 mg\u002FmL, despite growth promotion testing failing twice and passing on a third test. Your investigation concluded there was no product impact because retesting of the media ultimately achieved passing results. Your investigation documented human performance as the cause of the failing testing events for (b)(4), lot (b)(4), and (b)(4) other media lots; however, no specific human error was identified.\nYour initial response acknowledged the investigation did not adequately document the evidence supporting the identified root cause despite the availability of test data. You also committed to revise SOP-000147 to require investigations for any confirmed or unconfirmed growth promotion failure and you plan to hire a third-party consultant to perform a retrospective review of investigations and train personnel.\nYour initial response was inadequate. Your initial response did not include a copy of your revised procedure for “Quality Control Testing of Microbiological Test Media”, SOP-000147, to support your commitments to require investigations for all test failures and associated training for all analysts. Additionally, your investigation does not include a review of all failing growth promotion media for all application drug product batches tested using these media lots. Your initial response also did not provide protocols for your proposed retrospective assessments.\nb. You invalidated, without an adequate root cause investigation, out-of-specification (OOS) results for sub-visible particulate matter testing of (b)(4) batches of sodium bicarbonate injection when one of (b)(4) vials failed. Your investigation documented that (b)(4) were observed in the sample (b)(4) for the failing vial, and the analyst was instructed to (b)(4) the line to clear the (b)(4). When a retest of the vial did not confirm the original results, you prepared new vials which gave passing results. Although you identified the root cause as related to human error, no corrective action or training was implemented to prevent recurrence.\nYour initial response stated the root cause was due to (b)(4) in the sample (b)(4) and acknowledged that the analyst failed to follow the procedure. You stated you will revise your testing procedure “to include (b)(4) requirement for product that contains (b)(4)” … “to address any future human errors related to the dissipation of (b)(4) for particulate matter analysis.”\nYour initial response was inadequate. Although your response indicates there were two quality events (QE) in a 10-day span due to OOS (high) particulate matter counts, your investigation determined there was no “formal” trend and no corrective action was needed. The second QE-000622 included “(b)(4)” of the analyst to understand the importance of allowing time for (b)(4). However, your initial response did not include a copy of your revised procedure, QCMET-000074, “Determination of Particulate Matter in Finished Drug Products,” and documentation to show all analysts who perform this test method have been retrained to prevent recurrence.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequately scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nYou failed to accurately document microbiology testing results. In addition, test results are not verified by a second person for accuracy. Specifically, on November 6, 2024, your analyst recorded fewer colony forming units for active air environmental monitoring samples than what was observed by our investigator during the examination. An independent review of the plate count by a second analyst to assure accuracy of the data was not conducted.\nReliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the quality unit’s ability to exercise its function of ensuring compliance to applicable standards.\nYour initial response acknowledged “a secondary, contemporaneous verification of environmental monitoring samples is fundamental to maintaining the integrity of such data.” You also committed to revise your procedures to require a second person review for all tests and to perform a retrospective review of “microbiology laboratory activities to identify activities that are not currently recorded electronically or contemporaneously.”\nYour initial response was inadequate because it failed to address the misread plate counts observed during the inspection for viable air and identify corrective and preventative actions for this failure. Moreover, your response lacks an assessment of potential data integrity concerns associated with one-person verification.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nII. Outsourcing Facility Operations\nYou also registered your facility with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b]1 on June 6, 2014, initially, and most recently on January 1, 2024. Your facility deregistered as an outsourcing facility on December 20, 2024. We acknowledge your stated intent to discontinue production and distribution of 503B products effective January 31, 2025. As described below, the violations described in this letter are based on the observations in the most recent inspection and subsequent analysis, and they would continue to apply should you resume producing drug products intended to meet the conditions of section 503B.\nDuring the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nA. Compounded Drug Products under the FD&C Act\nUnder section 503B(b) of the FD&C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FD&C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&C Act are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FD&C Act [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FD&C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nB. Violations of the FD&C Act\nAdulterated Drug Products\nThe FDA investigators noted CGMP violations at your outsourcing facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act. The violations include, for example:\n1. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n2. Your firm failed to conduct laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.167(a)).\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n4. Laboratory records are deficient in that they do not include the initials and signature of the second person reviewing the record for accuracy (21 CFR 211.194(a)(8)).\n5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n6. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\n7. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FD&C Act. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s current thinking regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FD&C Act [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FD&C Act [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483. We acknowledge that your facility deregistered as an outsourcing facility on December 20, 2024.\nSome of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\nRegarding your firm’s process validation for (b)(4) cycles used to (b)(4) sterilize Sodium Chloride Injection 0.9% USP in 500mL IV bags being performed using (b)(4) and not the drug product, you state that notwithstanding your discussion regarding this observation, “Exela understands the Agency’s position in raising this issue. If the 503B program continues, pending further discussions with the Agency, Exela intends to validate the (b)(4) cycles for 0.9% Sodium Chloride Injection, 1000 mL IV bags using the actual product. This will be supplemented by sterility testing at release.” We acknowledge this commitment to performing the validations and sterility testing. If you decide to produce drugs intended or expected to be sterile in accordance with 503B, you would be subject to CGMPs, including conducting process validations for all drug products prior to their production and distribution.\nAdditionally, some of your corrective actions appear deficient:\n1. Your firm used (b)(4) media lot (b)(4) to release sterility testing of Sodium Acetate Injection (in vials). However, two tests of lot (b)(4) were invalidated and the third test was passed without scientific rationale. Your firm's investigation, QE-000487, states human performance was determined to be the root cause of the failed testing events. However, your firm did not document any specific human error identified when testing the (b)(4) media. Three other lots of test media ((b)(4) lot (b)(4), (b)(4) lot (b)(4), and (b)(4) lot (b)(4)) were documented in your firm's investigation, QE-000487, as failing initial GPT and passing retest, however, no root cause for these test failures were documented.\nIn your responses, you state there was no impact to finished drug product since the observation resulted from human error rather than the media itself, however, you did not provide in your response evidence as to how you determined human error was the sole reason for the failed tests. In addition, your responses did not identify the source of the human error, or identify any improper techniques utilized by analyst(s) during the testing.\n2. You failed to perform contemporaneous two-person checks during the reading of environmental (b)(4) plates and subsequent data entry of the results in your (b)(4) software system. A single analyst reads environmental plate counts, takes pictures only of the positive counts, and then enters results in the (b)(4) software system. The Quality Control (QC) personnel later review and verify the results in the (b)(4) software system. There is no assurance the analyst read plate counts accurately or entered data in the software system accurately. On November 6, 2024, an FDA investigator observed miscounted plates with discrepancies when compared to the analyst’s count which were later corrected by the analyst.\nIn your responses, you state that section 6.8.7.5 of your SOP-000189 “Use, Preparation, and Storage of QC – Microbiology Laboratory Media” has been revised. However, the revision does not clearly define when or how the second verifier will “…visually verify the presence or absence of microbiological growth….” Nor does the SOP address required timeframes as to when the second person will verify growth and ensure data is entered timely and correctly in the (b)(4) system. As written, the SOP fails to ensure contemporaneous QC review of plate counts and data accuracy.\n3. Regarding your failing to have stability data to support a six-month expiration date for Sodium Chloride 0.9%, USP packaged in 500 mL polypropylene IV bags from a batch size of (b)(4) produced on the “(b)(4)” line in the (b)(4) building, your firm was not adhering to your SOP-QA-000064, “Stability Policy and Guidelines for Establishing Expiration Date or Beyond Use Date of 503B Product.” Section 6.1.5, of the SOP, states stability protocols will be established, and studies will be conducted for variations of 503B products. Your response states you have discontinued the 503B program and are no longer 503B registered. If you decide to produce drugs in accordance with 503B, the establishment of stability protocols are expected to be completed and studies to be in process before producing and distributing finished drug product.\nWe note that you refer to the “Temporary Policies for Compounding Certain Parenteral Drug Products Guidance for Industry, October 2024” in your response. It appears that your FDA 483 response may incorrectly describe some of the conditions discussed in this guidance. Should you resume production, in accordance with 503B, with the intent to qualify for the temporary policies described in this guidance, you should review it, particularly the conditions including using a default BUD of not more than 28 days at room temperature and not more than 42 days refrigerated when a sterility test has not been completed before release; the initiation of limited stability testing once the aggregate batch size of the product is expected to exceed 5,000 units; and initiation of CCIT with the first batch.\n4. Regarding your firm’s visual inspection program, you committed to developing improvements to your existing visual inspection program, however, no information was provided of what you will do in the meantime before all the corrections have been made, evaluated, and revised, if needed, along with training. In addition, we have the following concerns with your planned corrections:\nYou state that your defect rates will be based on (b)(4) Visual Inspection of Medicinal Products for Parenteral Use standards. You did not provide any details explaining your rationale for using the (b)(4) or (b)(4) standards.\nDeficiencies on the risk assessment of your visual inspection program and process.\ni. Your risk assessment explains (b)(4) defects ((b)(4)) were not physically represented in the library of defects and concluded that they did not impact the integrity of the unit and, therefore, would have no impact on the patient. However, no information was provided as to why these (b)(4) defects would not impact the integrity of the unit or why the damaged (b)(4) was classified as a major defect rather than critical.\nii. Your risk assessment stated, “From the risk ratings and review of other data, although the test sets did not include an example of each defect type identified in SOP-000266, this assessment provides confidence that the robust training program provided adequate training on the identification of defects through the training hours in conjunction with the visual aid of defects….” This assessment appears flawed as it is based on test sets not including an example of each defect type and based on (b)(4) data rather than data collected during the visual inspection phase.\niii. It is not apparent if your risk assessment considered whether particulates could be inherent, intrinsic, or extrinsic in nature. It is not clear whether you have established defect (b)(4) with known inherent, intrinsic, or extrinsic defects for particulates. Therefore, it is not known whether visual inspectors can identify those defects during visual inspection. Furthermore, you are classifying all particulates as major defects, and your rationale for this classification is not provided.\nYour training or requalification time of (b)(4) periods does not reflect actual visual inspection conditions as documented in your batch record visual inspection worksheets.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FD&C Act. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)]\nFDA strongly recommends that if you decide to resume compounding and distribution of sterile drugs your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nIII. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nIf you decide to resume operations under section 503B of the FD&C Act, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nAs part of your response, please verify in writing your continuing intention to not resume operations under section 503B of the FD&C Act. If you intend to resume such operations in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. In addition to taking appropriate corrective actions, you should also notify us fifteen (15) working days prior to resuming production of drugs under section 503B of the FD&C Act in the future by contacting compoundinginspections@fda.hhs.gov.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008563008 and ATTN: Erika V. Butler.\nWe also recommend that, after you submit your response, you submit a Post-Warning Letter Meeting3 request to: FDA-GDUFAIII-PostWarningLetterandReinspectionRequests@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans. Please see the Guidance for Industry “Post-Warning Letter Meetings Under GDUFA” for more information: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F171785\u002Fdownload","Exela Pharma Sciences, LLC","exela-pharma-sciences-llc-709859-07022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexela-pharma-sciences-llc-709859-07022025","2026-10-26T08:08:38.306208+00:00","2025-07-03","709859","Phanesh Koneru, PhD, LL.M.","2026-08-19T16:37:52.368+00:00","320-25-88","2025-07-02",{"id":174,"raw":175,"subject":38,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":48,"closeout_date":19,"issuing_office":179,"recipient_name":189,"body_fetched_at":190,"delivery_method":191,"recipient_title":19,"reference_number":192,"action_taken_date":193,"medical_device_id":19,"response_letter_date":19},1073,[176,177,178,179,37,13,13,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025\">BioStem Life Sciences\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-673788\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason V. Matuszewski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioStem Life Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2836 Center Port Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quality@biostemtech.com\"> quality@biostemtech.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>January 17, 2025&nbsp;\u003C\u002Fp>\u003Cp>CBER 25-673788\u003C\u002Fp>\u003Cp>Dear Mr. Matuszewski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).&nbsp;\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cp>NEOFYL®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”&nbsp;\u003C\u002Fp>\u003Cp>o &nbsp;“The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\u003C\u002Fp>\u003C\u002Fli>\u003Cli>OROPRO®\u003Cbr>o &nbsp;“Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\u003Cbr>o &nbsp;“Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\u003C\u002Fli>\u003Cli>PROVISCUS®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\u003C\u002Fli>\u003Cli>RHEO®\u003Cbr>o &nbsp;“RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\u003Cp>a. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\u003C\u002Fp>\u003Cp>b. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These are not sufficient measures of identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>Process validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> For example, your firm assigned expiration dates between \u003Cstrong>(b)(4)\u003C\u002Fstrong> months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility testing only while Product 401 (OROPRO®) is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-month shelf life and remain within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>We note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., USP&lt;1&gt; (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-673788\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJason V. Matuszewski\n\nRecipient Title\n\nChief Executive Officer\n\nBioStem Life Sciences\n\n2836 Center Port Circle\n\nPompano Beach, FL 33064\n\nUnited States\n\nquality@biostemtech.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJanuary 17, 2025\nCBER 25-673788\nDear Mr. Matuszewski:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nNEOFYL®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”\no “The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\n\nOROPRO®\no “Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\no “Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\nPROVISCUS®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\nRHEO®\no “RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)]. For example,\na. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., (b)(4) where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\nb. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\n2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 (b)(4) and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to (b)(4). These are not sufficient measures of identity, strength, quality, and purity.\nProcess validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\n5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. For example, your firm assigned expiration dates between (b)(4) months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to (b)(4) sterility testing only while Product 401 (OROPRO®) is limited to (b)(4) sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\nResponses to the Form FDA-483\nWe acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a (b)(4)-month shelf life and remain within expiry.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nWe note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.2 FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.3 Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n________________________\n1 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\n2 The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\n3 See, e.g., USP\u003C1> (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).","BioStem Life Sciences","biostem-life-sciences-673788-01172025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025","2026-10-26T08:08:05.524573+00:00","2025-02-04","673788","Jason V. Matuszewski","2026-08-19T17:02:42.585+00:00","VIA UPS and Electronic Mail","CBER 25-673788","2025-01-17",{"id":195,"raw":196,"subject":202,"body_html":203,"body_text":204,"firm_name":205,"letter_id":206,"created_at":207,"fei_number":19,"letter_url":208,"updated_at":209,"action_type":22,"case_status":23,"posted_date":210,"marcs_cms_no":211,"product_type":212,"closeout_date":19,"issuing_office":200,"recipient_name":213,"body_fetched_at":214,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":215,"medical_device_id":19,"response_letter_date":19},1787,[197,198,199,200,201,13,13,13],"\u003Ctime datetime=\"2023-10-24T13:20:00Z\">10\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-04T04:00:00Z\">10\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fembryll-life-sciences-inc-668858-10042023\">Embryll Life Sciences, Inc.\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug\u002FAdulterated\u003Cbr \u002F>\r\n","Unapproved New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Diana Rodriguez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CCO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Embryll Life Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>651 N Broad St, Suite 206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19709\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@embryll.com\"> support@embryll.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nOctober 04, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Re: 668858\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Diana Rodriguez:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s marketing of an unapproved new animal drug product, Lanomax®, for the treatment of cataracts in animals. The United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.lanomax.com in August and September 2023 and has determined that you promote and offer this product for sale there.\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website at the internet address https:\u002F\u002Fwww.lanomax.com, your Lanomax® product is a drug under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>Currently there are no FDA-approved eye drops for use in animals that are labeled for treating, preventing, mitigating, or curing cataracts. Your product, which claims to treat this condition, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of claims FDA observed on your website and product labeling that show the intended use of your Lanomax® product include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>From your home website titled “\u003Cstrong>LANOMAX\u003C\u002Fstrong>®” at the URL https:\u002F\u002Fwww.lanomax.com\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lanomax® is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.”\u003C\u002Fli>\n\t\u003Cli>“…in the case of incipient, immature, and mature cataracts, if you administer two vials of Lanomax® eye drops to one eye for six weeks, you will see visible improvements compared to the untreated eye.”\u003C\u002Fli>\n\t\u003Cli>“…there are dramatic cases where a visible effect is even noticed within a short period of 1-2 weeks after beginning to administer Lanomax®.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your webpage titled “\u003Cstrong>LANOMAX\u003C\u002Fstrong>®” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Flanomax.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lanomax® can cure cataracts in the form of eye drops alone…”\u003C\u002Fli>\n\t\u003Cli>“Lanomax® uses ThruDelivery®, an innovative drug delivery system built using the latest advanced nanotechnology…It is because of this ThruDelivery® system that Lanomax® is the only eye drop on the planet to show a real therapeutic effect on cataracts.”\u003C\u002Fli>\n\t\u003Cli>“Currently, this amazing lanosterol delivery system is only found in Lanomax® eye drops.”\u003C\u002Fli>\n\t\u003Cli>“Lanomax® has an excellent therapeutic effect on incipient, immature, and mature cataracts.”\u003C\u002Fli>\n\t\u003Cli>“The therapeutic effect of Lanomax® varies greatly depending on the type of cataract and the degree of its progression.”\u003C\u002Fli>\n\t\u003Cli>“Sometimes there are dramatic cases where a visible effect can even be noticed within a short period of 1-2 weeks beginning to administer Lanomax®.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your webpage titled “\u003Cstrong>FAQ\u003C\u002Fstrong>” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Ffaq.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Can Lanomax® be used for animals such as birds, minks or horses? Lanomax® can be used for cataracts that occur in all kinds of animals.”\u003C\u002Fli>\n\t\u003Cli>“Can I use Lanomax® for animals with diabetes? Lanomax® is safe for use on animals with age-related diseases, including diabetes.”\u003C\u002Fli>\n\t\u003Cli>“Can Lanomax® be used on animals with glaucoma? Does it increase the intraocular pressure? Lanomax® is safe for use on animals with glaucoma; it will not affect the intraocular pressure.”\u003C\u002Fli>\n\t\u003Cli>“Do I need a prescription and veterinarian involved to use Lanomax®? No, Lanomax® does not require consulting a veterinarian or getting a prescription.”\u003C\u002Fli>\n\t\u003Cli>“During the use of Lanomax®, the cataracts split into multiple fragments. What causes this? It is a desirable phenomenon to see the protein aggregation (the cause of cataract) is dissolving. This is nothing to be alarmed about and you should continue the treatment.”\u003C\u002Fli>\n\t\u003Cli>“Must I continue to use Lanomax® after the cataracts are completely cured? … you may want to continue to use a low dose of Lanomax® as a preventative measure against the recurrence of cataracts.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage titled “\u003Cstrong>Reviews\u003C\u002Fstrong>” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Freviews.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"…I found out about Lanomax…the progression has stopped and his eyes have remained stable every [sic] since…”\u003C\u002Fli>\n\t\u003Cli>\"…was completely blind due to diabetic cataracts. Thanks to Lanomax, his cataracts are dissolving and he can see again…”\u003C\u002Fli>\n\t\u003Cli>\"…I'm writing to tell you your lanomax eye drops helped my dogs [sic] vision immensely…”\u003C\u002Fli>\n\t\u003Cli>\"Just want you to know that Lanomax is helping…He can see something out of his cataract eye [sic] that is not hyper mature.”\u003C\u002Fli>\n\t\u003Cli>\"…has severe cataract on his left eye. We have applied Lanomax on both eyes…We think Lanomax is also helping the right eye from developing cataract.\"\u003C\u002Fli>\n\t\u003Cli>\"Lanomax works well and my dog's vision has improved…”\u003C\u002Fli>\n\t\u003Cli>\"To all who have cataract animals!! This product truly works…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This product is a new animal drug under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 668858” in the subject line of\u003Cbr>\nyour email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>Cc: media@embryll.com\u003Cbr>\nsupport@lanomax.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDiana Rodriguez\n\nRecipient Title\n\nCCO\n\nEmbryll Life Sciences, Inc.\n\n651 N Broad St, Suite 206\n\nMiddletown, DE 19709\n\nUnited States\n\nsupport@embryll.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nOctober 04, 2023\n\nRe: 668858\n\nDear Diana Rodriguez:\n\nThis letter concerns your firm’s marketing of an unapproved new animal drug product, Lanomax®, for the treatment of cataracts in animals. The United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.lanomax.com in August and September 2023 and has determined that you promote and offer this product for sale there.\n\nBased on our review of your website at the internet address https:\u002F\u002Fwww.lanomax.com, your Lanomax® product is a drug under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nCurrently there are no FDA-approved eye drops for use in animals that are labeled for treating, preventing, mitigating, or curing cataracts. Your product, which claims to treat this condition, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of claims FDA observed on your website and product labeling that show the intended use of your Lanomax® product include, but are not limited to the following:\n\nFrom your home website titled “LANOMAX®” at the URL https:\u002F\u002Fwww.lanomax.com\u002F:\n\n“Lanomax® is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.”\n\n“…in the case of incipient, immature, and mature cataracts, if you administer two vials of Lanomax® eye drops to one eye for six weeks, you will see visible improvements compared to the untreated eye.”\n\n“…there are dramatic cases where a visible effect is even noticed within a short period of 1-2 weeks after beginning to administer Lanomax®.”\n\nFrom your webpage titled “LANOMAX®” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Flanomax.html:\n\n“Lanomax® can cure cataracts in the form of eye drops alone…”\n\n“Lanomax® uses ThruDelivery®, an innovative drug delivery system built using the latest advanced nanotechnology…It is because of this ThruDelivery® system that Lanomax® is the only eye drop on the planet to show a real therapeutic effect on cataracts.”\n\n“Currently, this amazing lanosterol delivery system is only found in Lanomax® eye drops.”\n\n“Lanomax® has an excellent therapeutic effect on incipient, immature, and mature cataracts.”\n\n“The therapeutic effect of Lanomax® varies greatly depending on the type of cataract and the degree of its progression.”\n\n“Sometimes there are dramatic cases where a visible effect can even be noticed within a short period of 1-2 weeks beginning to administer Lanomax®.”\n\nFrom your webpage titled “FAQ” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Ffaq.html:\n\n“Can Lanomax® be used for animals such as birds, minks or horses? Lanomax® can be used for cataracts that occur in all kinds of animals.”\n\n“Can I use Lanomax® for animals with diabetes? Lanomax® is safe for use on animals with age-related diseases, including diabetes.”\n\n“Can Lanomax® be used on animals with glaucoma? Does it increase the intraocular pressure? Lanomax® is safe for use on animals with glaucoma; it will not affect the intraocular pressure.”\n\n“Do I need a prescription and veterinarian involved to use Lanomax®? No, Lanomax® does not require consulting a veterinarian or getting a prescription.”\n\n“During the use of Lanomax®, the cataracts split into multiple fragments. What causes this? It is a desirable phenomenon to see the protein aggregation (the cause of cataract) is dissolving. This is nothing to be alarmed about and you should continue the treatment.”\n\n“Must I continue to use Lanomax® after the cataracts are completely cured? … you may want to continue to use a low dose of Lanomax® as a preventative measure against the recurrence of cataracts.”\n\nOn your webpage titled “Reviews” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Freviews.html:\n\n\"…I found out about Lanomax…the progression has stopped and his eyes have remained stable every [sic] since…”\n\n\"…was completely blind due to diabetic cataracts. Thanks to Lanomax, his cataracts are dissolving and he can see again…”\n\n\"…I'm writing to tell you your lanomax eye drops helped my dogs [sic] vision immensely…”\n\n\"Just want you to know that Lanomax is helping…He can see something out of his cataract eye [sic] that is not hyper mature.”\n\n\"…has severe cataract on his left eye. We have applied Lanomax on both eyes…We think Lanomax is also helping the right eye from developing cataract.\"\n\n\"Lanomax works well and my dog's vision has improved…”\n\n\"To all who have cataract animals!! This product truly works…”\n\nThis product is a new animal drug under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 668858” in the subject line of\n\nyour email.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nCc: media@embryll.com\n\nsupport@lanomax.com","Embryll Life Sciences, Inc.","embryll-life-sciences-inc-668858-10042023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fembryll-life-sciences-inc-668858-10042023","2026-10-26T08:08:34.981632+00:00","2023-10-24","668858","Animal & VeterinaryDrugs","Diana Rodriguez","2026-08-20T00:34:53.678+00:00","2023-10-04",{"id":217,"raw":218,"subject":224,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":229,"fei_number":19,"letter_url":230,"updated_at":231,"action_type":22,"case_status":23,"posted_date":232,"marcs_cms_no":233,"product_type":26,"closeout_date":19,"issuing_office":222,"recipient_name":234,"body_fetched_at":235,"delivery_method":111,"recipient_title":19,"reference_number":19,"action_taken_date":236,"medical_device_id":19,"response_letter_date":19},3382,[219,220,221,222,223,13,13,13],"\u003Ctime datetime=\"2021-04-27T13:20:00Z\">04\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-08T04:00:00Z\">04\u002F08\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexela-pharma-sciences-llc-611316-04082021\">Exela Pharma Sciences LLC\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","Unapproved New Drug\u002FCompounding\u002FMisbranding\u003Cbr \u002F>\r\n","Unapproved New Drug\u002FCompounding\u002FMisbranding","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Phanesh B. Koneru\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Exela Pharma Sciences LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1245 Blowing Rock Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lenoir\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>28645-3618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 8, 2021\u003C\u002Fp>\n\n\u003Cp>Case #: 611316\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dr. Koneru:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on June 6, 2014, and most recently on November 16, 2020. From June 10, 2019 to July 18, 2019, an FDA investigator inspected your facility Exela Pharma Sciences, LLC located at 1245 Blowing Rock Blvd., Lenoir, NC 28645 and 1325 William White Place, Lenoir, NC 28645. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on July 18, 2019. FDA acknowledges receipt of your facility’s correspondence, dated August 8, 2019, June 9, 2020, and June 12, 2020. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of section 503B of the FDCA [21 U.S.C. § 353b]. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (see section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. §353b(a)(1), (b)(5)]).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. Evidence collected indicates that your facility’s drug products were not compounded in an outsourcing facility that is in compliance with the requirements of section 503B(b) (see section 503B(a)(1) of the FDCA). In particular, your facility does not comply with section 503B(b)(5) of the FDCA, which as noted above, requires an outsourcing facility to submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, at the time of the inspection, your documented procedures only covered “NDA\u002FANDA products” and makes no reference to the required adverse event submission process utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self- diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>You did not address certain issues related to the conditions of section 503B of the FDCA, for example: we have reviewed the Standard Operating Procedure (SOP) you submitted concerning adverse event reporting. We note that this SOP does not appear to adequately address adverse event reporting. For example, your SOP makes no reference to the required adverse event submission process utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\u003C\u002Fp>\n\n\u003Cp>As explained above, a facility must comply with adverse event reporting requirements (section 503B(b)(5) of the FDCA [21 U.S.C. §353b(b)(5)]) in order to qualify for the exemptions under section 503B. The SOP you have adopted does not comply with these requirements, because it provides inadequate instructions for reporting. Furthermore, your procedures for adverse event reporting must also comply with the requirements as specified in 21 C.F.R. 211.198.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The issues cited in this letter are not intended to be an all-inclusive list of potential violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the issues cited in this letter. Failure to promptly correct these violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address the issues identified. Please include an explanation of each step being taken to prevent the recurrence, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot address these issues within fifteen (15) working days, state the reason for the delay and the time within which you will finish addressing them.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>611316\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to John Diehl, Director, Compliance Branch, via john.diehl@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Ms. Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov .\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMonica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For more information, see FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at&nbsp;https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM4341 88.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nPhanesh B. Koneru\n\nRecipient Title\n\nPresident & CEO\n\nExela Pharma Sciences LLC\n\n1245 Blowing Rock Blvd.\n\nLenoir, NC 28645-3618\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nApril 8, 2021\n\nCase #: 611316\n\nWARNING LETTER\n\nDr. Koneru:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on June 6, 2014, and most recently on November 16, 2020. From June 10, 2019 to July 18, 2019, an FDA investigator inspected your facility Exela Pharma Sciences, LLC located at 1245 Blowing Rock Blvd., Lenoir, NC 28645 and 1325 William White Place, Lenoir, NC 28645. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA.\n\nFDA issued a Form FDA 483 to your facility on July 18, 2019. FDA acknowledges receipt of your facility’s correspondence, dated August 8, 2019, June 9, 2020, and June 12, 2020. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of section 503B of the FDCA [21 U.S.C. § 353b]. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (see section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. §353b(a)(1), (b)(5)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. Evidence collected indicates that your facility’s drug products were not compounded in an outsourcing facility that is in compliance with the requirements of section 503B(b) (see section 503B(a)(1) of the FDCA). In particular, your facility does not comply with section 503B(b)(5) of the FDCA, which as noted above, requires an outsourcing facility to submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).3 Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, at the time of the inspection, your documented procedures only covered “NDA\u002FANDA products” and makes no reference to the required adverse event submission process utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self- diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483.\n\nYou did not address certain issues related to the conditions of section 503B of the FDCA, for example: we have reviewed the Standard Operating Procedure (SOP) you submitted concerning adverse event reporting. We note that this SOP does not appear to adequately address adverse event reporting. For example, your SOP makes no reference to the required adverse event submission process utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\n\nAs explained above, a facility must comply with adverse event reporting requirements (section 503B(b)(5) of the FDCA [21 U.S.C. §353b(b)(5)]) in order to qualify for the exemptions under section 503B. The SOP you have adopted does not comply with these requirements, because it provides inadequate instructions for reporting. Furthermore, your procedures for adverse event reporting must also comply with the requirements as specified in 21 C.F.R. 211.198.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nE. Conclusion\n\nThe issues cited in this letter are not intended to be an all-inclusive list of potential violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the issues cited in this letter. Failure to promptly correct these violations may result in legal action, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address the issues identified. Please include an explanation of each step being taken to prevent the recurrence, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot address these issues within fifteen (15) working days, state the reason for the delay and the time within which you will finish addressing them.\n\nYour written notification should refer to case # 611316.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to John Diehl, Director, Compliance Branch, via john.diehl@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Ms. Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov .\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II\n\n_________________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 For more information, see FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM4341 88.pdf.\n\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Exela Pharma Sciences LLC","exela-pharma-sciences-llc-611316-04082021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexela-pharma-sciences-llc-611316-04082021","2026-10-26T08:08:38.257609+00:00","2021-04-27","611316","Phanesh B. Koneru","2026-08-20T03:10:39.844+00:00","2021-04-08",{"id":238,"raw":239,"subject":244,"body_html":246,"body_text":247,"firm_name":248,"letter_id":249,"created_at":43,"fei_number":19,"letter_url":250,"updated_at":251,"action_type":22,"case_status":252,"posted_date":253,"marcs_cms_no":254,"product_type":255,"closeout_date":256,"issuing_office":243,"recipient_name":257,"body_fetched_at":258,"delivery_method":259,"recipient_title":19,"reference_number":19,"action_taken_date":260,"medical_device_id":19,"response_letter_date":19},2340,[240,241,242,243,244,13,245,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022\">Calroy Health Sciences, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-07192023\">\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chen and Mr. Hoyt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Calroy Health Sciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14362 N Frank Lloyd Wright, Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636311\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen and Mr. Hoyt:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Arterosil product page at www.arterosil.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Under the “Patient Education” Tab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; &nbsp;and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chen and Mr. Hoyt\n\nCalroy Health Sciences, LLC\n\n14362 N Frank Lloyd Wright, Suite 1000\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636311\n\nDear Mr. Chen and Mr. Hoyt:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\n\nOn your Arterosil product page at www.arterosil.com:\n\n\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\n\n“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\n\n\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\n\nUnder the “Patient Education” Tab\n\n\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\n\n\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\n\n\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\n\n\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\n\n\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\n\nYour Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","Calroy Health Sciences, LLC","calroy-health-sciences-llc-636311-11142022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022","2026-10-26T08:08:10.528128+00:00","Closed Out","2022-11-17","636311","Dietary SupplementsDrugs","2023-07-21","Mr. Chen and Mr. Hoyt","2026-08-20T01:25:36.732+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":262,"raw":263,"subject":244,"body_html":270,"body_text":271,"firm_name":272,"letter_id":273,"created_at":229,"fei_number":19,"letter_url":274,"updated_at":275,"action_type":22,"case_status":252,"posted_date":276,"marcs_cms_no":277,"product_type":278,"closeout_date":279,"issuing_office":267,"recipient_name":280,"body_fetched_at":281,"delivery_method":282,"recipient_title":19,"reference_number":19,"action_taken_date":283,"medical_device_id":19,"response_letter_date":19},3011,[264,265,266,267,268,13,269,13],"\u003Ctime datetime=\"2021-11-30T14:20:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-18T05:00:00Z\">11\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021\">Saffron Health Sciences\u003C\u002Fa>","Division of Human and Animal Food Operations East II","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-01182022\">\u003Ctime datetime=\"2022-02-15T05:00:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Song Gao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Saffron Health Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 Dexter Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>E Brunswick\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08816-2873\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #615429\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 18, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Gao;\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at&nbsp;\u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\u003C\u002Fli>\n\t\u003Cli>“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\u003C\u002Fli>\n\t\u003Cli>“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\u003C\u002Fli>\n\t\u003Cli>“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\u003C\u002Fli>\n\t\u003Cli>“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The neuroprotective effects of crocin against stroke is the focus of this article.”\u003C\u002Fli>\n\t\u003Cli>“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNF\u003Cspan>\u003Cspan>a\u003C\u002Fspan>\u003C\u002Fspan>), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\u003Cbr>\n&nbsp; &nbsp; o “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\u003Cbr>\n&nbsp; &nbsp; o “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\u003C\u002Fp>\n\n\u003Cp>From the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\u003C\u002Fli>\n\t\u003Cli>“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\u003C\u002Fli>\n\t\u003Cli>“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\u003C\u002Fli>\n\t\u003Cli>“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\u003C\u002Fli>\n\t\u003Cli>“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\u003C\u002Fli>\n\t\u003Cli>“Crocin also significantly improved International Index of Erectile Functions ....”\u003C\u002Fli>\n\t\u003Cli>“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the section of your webpage titled “Crocin &amp; Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin is … a potent … anti-inflammatory agent.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\u003C\u002Fli>\n\t\u003Cli>“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895170&amp;s=merchant-items&amp;sr=1-2):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895736&amp;s=merchant-items&amp;sr=1-1):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Posted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\u003C\u002Fli>\n\t\u003Cli>Posted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\u003C\u002Fli>\n\t\u003Cli>Posted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Randy F. Pack\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision Director\u003Cbr>\nHuman &amp; Animal Food Division II East\u003Cbr>\nBaltimore District Office\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Song Gao\n\nSaffron Health Sciences\n\n13 Dexter Rd\n\nE Brunswick, NJ 08816-2873\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS #615429\n\nNovember 18, 2021\n\nDear Dr. Gao;\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people1. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\n\n“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\n\n“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\n\n“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\n\n“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\n\nFrom the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\n\n“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\n\n“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\n\n“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\n\n“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\n\n“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\n\n“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\n\nFrom the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\n\n“The neuroprotective effects of crocin against stroke is the focus of this article.”\n\n“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\n\n“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\n\nFrom the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\n\n“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\n\no “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNFa), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\n\no “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\n\no “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\n\nFrom the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\n\n“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\n\n“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\n\n“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\n\nFrom the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\n\n“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\n\n“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\n\n“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\n\nFrom the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\n\n“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\n\n“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\n\n“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\n\n“Crocin also significantly improved International Index of Erectile Functions ....”\n\n“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\n\nOn your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\n\n“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\n\nOn your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\n\n“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\n\nFrom the section of your webpage titled “Crocin & Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\n\n“Crocin is … a potent … anti-inflammatory agent.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\n\n“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\n\n“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895170&s=merchant-items&sr=1-2):\n\n“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895736&s=merchant-items&sr=1-1):\n\n“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\n\nExamples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\n\nPosted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\n\nPosted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\n\nPosted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\n\nYour Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\n\nSincerely,\n\n\u002FS\u002F\n\nRandy F. Pack\n\nProgram Division Director\n\nDivision Director\n\nHuman & Animal Food Division II East\n\nBaltimore District Office\n\n___________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.","Saffron Health Sciences","saffron-health-sciences-615429-11182021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021","2026-10-26T08:09:52.649006+00:00","2021-11-30","615429","DrugsFood & Beverages","2022-02-15","Dr. Song Gao","2026-08-20T02:23:11.401+00:00","VIA UPS","2021-11-18",{"id":285,"raw":286,"subject":80,"body_html":290,"body_text":291,"firm_name":292,"letter_id":293,"created_at":294,"fei_number":19,"letter_url":295,"updated_at":296,"action_type":22,"case_status":23,"posted_date":297,"marcs_cms_no":298,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":299,"body_fetched_at":300,"delivery_method":301,"recipient_title":19,"reference_number":302,"action_taken_date":303,"medical_device_id":19,"response_letter_date":19},21634,[287,288,289,11,80,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freliance-life-sciences-private-limited-730801-08182026\">Reliance Life Sciences Private Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-117\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Santhosh Mathai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Business Head-Pharmaceuticals\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Reliance Life Sciences Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Dhirubhai Ambani Life Sciences Centre\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>R-282 Ttc Area of MIDC, Thane Belapur Road, Rabale\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Navi Mumbai\u003C\u002Fspan> \u003Cspan>400701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-117\u003C\u002Fp>\u003Cp>To Mr. Santhosh Mathai:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Reliance Life Sciences Private Limited, FDA Establishment Identifier (FEI) 3009510975, at Dhirubhai Ambani Life Sciences Centre, R-282 Ttc Area Of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra, 400701 India, from February 19 to February 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inaccurate Microbiology Laboratory Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to accurately document microbiology testing results. Specifically, multiple environmental monitoring and \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were documented in logbooks as collected and incubated; however, the corresponding plates could not be located in incubators during the inspection. Colony forming unit (cfus) counts had been recorded as if incubation was actively in progress. In interviews conducted by your management, your analysts confirmed these samples were not collected.\u003C\u002Fp>\u003Cp>In addition, your Laboratory Information Management System (LIMS) did not include a dilution factor to calculate the number of cfus per gram or milliliter of product for microbial limit test results, as required by your own procedures and applicable compendial methods. By releasing drug products based solely on raw plate count averages entered into your LIMS without applying the required dilution factor, you lack scientific evidence that each batch conforms to predetermined specifications prior to distribution. Appropriate testing is an essential part of ensuring that the drug products you manufacture conform to CGMP.\u003C\u002Fp>\u003Cp>Collectively, these deficiencies indicate a significant risk of systematic underreporting of microbial findings, which directly undermines your firm's ability to ensure the safety and quality of drug products distributed to patients.\u003C\u002Fp>\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record data or to maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the ability of your quality unit (QU) to exercise its function of ensuring compliance to applicable standards and deprives you of the ability to adequately investigate deviations.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Electronic Records Controls\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not have adequate controls to prevent the deletion or overwriting of \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing electronic data. Specifically, reports were not saved with unique file names, resulting in data being overwritten after every \u003Cstrong>(b)(4)\u003C\u002Fstrong> tests. In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing was not performed for Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your firm has no means of tracking or retrieving records of failed leak tests. The lack of adequate electronic records controls undermines the reliability and integrity of your laboratory data.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity is critical to preventing product contamination. Routine \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity tests should be performed. The monitoring and maintenance program should identify and eliminate any \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacking integrity and minimize the possibility of placing a sterile product at risk.\u003C\u002Fp>\u003Cp>All data must be complete, accurate and retained to enable appropriate assessment and decisions by the QU. The lack of control over the integrity of your data raises questions about the authenticity and reliability of your analytical data and the quality of your drug products.\u003C\u002Fp>\u003Cp>Your response states “the unaccounted samples may have been misplaced”. This explanation is contradictory as it does not address the fact that your own analysts confirmed during management interviews that the microbiological samples were never collected, nor does it address the broader pattern of inaccurate recordkeeping identified during the inspection. Your response indicates your commitment to hiring third parties to conduct a data integrity remediation plan, risk assessment, and product impact assessment. Your response is inadequate. You do not provide sufficient detail including specific timelines and deliverables on your data integrity remediation plan, risk assessment and product assessment. Furthermore, your response does not define the scope of third-party oversight responsibilities or establish accountability measures for the remediation effort.\u003C\u002Fp>\u003Cp>Additionally, you acknowledge deficiencies in your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing controls” and conducted a retrospective review. Your response is inadequate because although you conclude there is, “no evidence of product contamination attributable to \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure”, the thoroughness of this review cannot fully support a definitive risk-based conclusion since you acknowledge that “historical traceability was incomplete”.\u003C\u002Fp>\u003Cp>We acknowledge your firm’s long-term commitment to improving your manufacturing operation, including, but not limited to, hiring additional microbiological laboratory staff and building a larger microbiological laboratory.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and\u003C\u002Fem> \u003Cem>Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We acknowledge that you are using independent third-party consultants to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\u003Cli>A retrospective review of all microbial limit test results to include the proper dilution factor to calculate the number of cfus per gram or milliliter of product for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis. Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o An indication of whether you plan to hire a data integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection identified aseptic processing design deficiencies that pose significant hazards to drug product sterility. During a mock filling operation and during review of your unidirectional smoke studies, our investigators observed multiple instances of inappropriate aseptic behavior in which operators blocked unidirectional airflow at critical locations without implementing appropriate corrective measures, including discarding potentially compromised vials. Specific examples include:\u003C\u002Fp>\u003Cul>\u003Cli>Blocking airflow over the stopper bowl and \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials while refilling the stopper bowl\u003C\u002Fli>\u003Cli>Passing forceps over the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and removing fallen vials from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials\u003C\u002Fli>\u003Cli>Blocking airflow during \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer operations, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> repositioning of filled vials onto a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and mechanical displacement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> via forceps\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Any compromise of first-air protection exposes sterile drug products to potential microbiological contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning, Decontamination, and Maintenance\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately clean, decontaminate, and maintain your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for aseptic drug product manufacturing. For example, our investigator observed multiple instances of deterioration and damage inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for manufacturing sterile drug products. These instances of deterioration and damage were not adequately addressed through your cleaning, decontamination, and maintenance programs. For example, our investigator observed:\u003C\u002Fp>\u003Cul>\u003Cli>Deteriorated \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank\u003C\u002Fli>\u003Cli>Excess sealant adjacent to the HEPA filters in the filling and \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas\u003C\u002Fli>\u003Cli>Use of nonsterile wipes soaked in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, our investigator observed accumulation of standing water and unknown \u003Cstrong>(b)(4)\u003C\u002Fstrong> staining on the wall surface adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> pipelines, located outside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room within the HVAC area.\u003C\u002Fp>\u003Cp>All equipment and associated operational areas should follow a reliable, comprehensive preventive maintenance program. This program should be designed to ensure sustained operational integrity through the systematic implementation of validated cleaning and disinfection protocols, as well as the proactive replacement of components before they deteriorate or degrade. Maintenance and change management procedures should prevent practices that may compromise equipment or introduce contamination risks.\u003C\u002Fp>\u003Cp>Aseptic processes need to be designed to minimize exposure of sterile articles to potential contamination hazards. A suitable monitoring system is critical to maintain appropriate environmental conditions throughout your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cleanrooms. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\u003C\u002Fp>\u003Cp>Your response states existing procedures \"did not adequately define acceptable hand positioning, intervention speed, first-air protection requirements, rejection criteria for potentially affected exposed units, or required actions following airflow interruption\" and acknowledges “equipment design and ergonomic limitations within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Additionally, you state you will not resume operations until “successful aseptic process simulation run incorporating all listed interventions under worst-case conditions are completed”. Furthermore, you commit to updating procedures for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization and cleaning to include sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> and sterile wipes. Your response also states that remediations were made to equipment, including repairing all sealant joints in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, smoothing internal machine surfaces to meet cleanability requirements, and updating maintenance checklists to include criteria for wear, damage, smoothness, cleanability, and material suitability.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient detail including deliverables on your third-party risk assessment of all aseptic filling lines. Additionally, your response does not sufficiently address the lack of oversight of operator aseptic behavior, equipment cleaning and maintenance, various manual activities, and intervention ergonomics.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive, independent risk assessment by a qualified consultant of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including, but not limited to, the following:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\u003Cbr>o Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\u003C\u002Fli>\u003Cli>A detailed remediation plan from the independent consultant with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms, the specific barrier system to be used (e.g., Restricted Access Barrier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and associated timelines. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall and Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 18, 2026, FDA held a teleconference with you recommending you consider removing any batches of sterile drugs currently in distribution from the U.S. market. On June 19, 2026, you agreed to recall all sterile drug products.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market.\u003C\u002Fp>\u003Cp>You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance prior to resumption of any manufacturing operations. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Reliance Life Sciences Private Limited, Navi Mumbai, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 3009510975 and ATTN: Claire Minden in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: Dr. Sandhya Narasimhan\u003Cbr>usagent1@masuuglobal.com\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-117\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Santhosh Mathai\n\nRecipient Title\n\nBusiness Head-Pharmaceuticals\n\nReliance Life Sciences Private Limited\n\nDhirubhai Ambani Life Sciences Centre\n\nR-282 Ttc Area of MIDC, Thane Belapur Road, Rabale\n\nNavi Mumbai 400701\n\nMaharashtra\n\nIndia\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nAugust 18, 2026\nWARNING LETTER\nReference number: 320-26-117\nTo Mr. Santhosh Mathai:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Reliance Life Sciences Private Limited, FDA Establishment Identifier (FEI) 3009510975, at Dhirubhai Ambani Life Sciences Centre, R-282 Ttc Area Of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra, 400701 India, from February 19 to February 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nInaccurate Microbiology Laboratory Records\nYou failed to accurately document microbiology testing results. Specifically, multiple environmental monitoring and (b)(4) samples were documented in logbooks as collected and incubated; however, the corresponding plates could not be located in incubators during the inspection. Colony forming unit (cfus) counts had been recorded as if incubation was actively in progress. In interviews conducted by your management, your analysts confirmed these samples were not collected.\nIn addition, your Laboratory Information Management System (LIMS) did not include a dilution factor to calculate the number of cfus per gram or milliliter of product for microbial limit test results, as required by your own procedures and applicable compendial methods. By releasing drug products based solely on raw plate count averages entered into your LIMS without applying the required dilution factor, you lack scientific evidence that each batch conforms to predetermined specifications prior to distribution. Appropriate testing is an essential part of ensuring that the drug products you manufacture conform to CGMP.\nCollectively, these deficiencies indicate a significant risk of systematic underreporting of microbial findings, which directly undermines your firm's ability to ensure the safety and quality of drug products distributed to patients.\nReliability of data is fundamentally compromised when there is a failure to record data or to maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the ability of your quality unit (QU) to exercise its function of ensuring compliance to applicable standards and deprives you of the ability to adequately investigate deviations.\nInadequate Electronic Records Controls\nYour firm did not have adequate controls to prevent the deletion or overwriting of (b)(4) integrity testing electronic data. Specifically, reports were not saved with unique file names, resulting in data being overwritten after every (b)(4) tests. In addition, (b)(4) integrity testing was not performed for Plant (b)(4). Therefore, your firm has no means of tracking or retrieving records of failed leak tests. The lack of adequate electronic records controls undermines the reliability and integrity of your laboratory data.\n(b)(4) integrity is critical to preventing product contamination. Routine (b)(4) integrity tests should be performed. The monitoring and maintenance program should identify and eliminate any (b)(4) lacking integrity and minimize the possibility of placing a sterile product at risk.\nAll data must be complete, accurate and retained to enable appropriate assessment and decisions by the QU. The lack of control over the integrity of your data raises questions about the authenticity and reliability of your analytical data and the quality of your drug products.\nYour response states “the unaccounted samples may have been misplaced”. This explanation is contradictory as it does not address the fact that your own analysts confirmed during management interviews that the microbiological samples were never collected, nor does it address the broader pattern of inaccurate recordkeeping identified during the inspection. Your response indicates your commitment to hiring third parties to conduct a data integrity remediation plan, risk assessment, and product impact assessment. Your response is inadequate. You do not provide sufficient detail including specific timelines and deliverables on your data integrity remediation plan, risk assessment and product assessment. Furthermore, your response does not define the scope of third-party oversight responsibilities or establish accountability measures for the remediation effort.\nAdditionally, you acknowledge deficiencies in your “(b)(4) integrity testing controls” and conducted a retrospective review. Your response is inadequate because although you conclude there is, “no evidence of product contamination attributable to (b)(4) failure”, the thoroughness of this review cannot fully support a definitive risk-based conclusion since you acknowledge that “historical traceability was incomplete”.\nWe acknowledge your firm’s long-term commitment to improving your manufacturing operation, including, but not limited to, hiring additional microbiological laboratory staff and building a larger microbiological laboratory.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe acknowledge that you are using independent third-party consultants to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\no A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\nA retrospective review of all microbial limit test results to include the proper dilution factor to calculate the number of cfus per gram or milliliter of product for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis. Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no An indication of whether you plan to hire a data integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nAn action plan and timelines for conducting full microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Practices\nOur inspection identified aseptic processing design deficiencies that pose significant hazards to drug product sterility. During a mock filling operation and during review of your unidirectional smoke studies, our investigators observed multiple instances of inappropriate aseptic behavior in which operators blocked unidirectional airflow at critical locations without implementing appropriate corrective measures, including discarding potentially compromised vials. Specific examples include:\nBlocking airflow over the stopper bowl and (b)(4) vials while refilling the stopper bowl\nPassing forceps over the (b)(4) and removing fallen vials from the (b)(4) and (b)(4) over (b)(4) vials\nBlocking airflow during (b)(4) transfer operations, including (b)(4) repositioning of filled vials onto a (b)(4) and mechanical displacement of (b)(4) vials into the (b)(4) via forceps\nAny compromise of first-air protection exposes sterile drug products to potential microbiological contamination.\nCleaning, Decontamination, and Maintenance\nYou failed to adequately clean, decontaminate, and maintain your (b)(4) used for aseptic drug product manufacturing. For example, our investigator observed multiple instances of deterioration and damage inside the (b)(4) used for manufacturing sterile drug products. These instances of deterioration and damage were not adequately addressed through your cleaning, decontamination, and maintenance programs. For example, our investigator observed:\nDeteriorated (b)(4) used to support the (b)(4) tank\nExcess sealant adjacent to the HEPA filters in the filling and (b)(4) areas\nUse of nonsterile wipes soaked in (b)(4) to clean (b)(4)\nIn addition, our investigator observed accumulation of standing water and unknown (b)(4) staining on the wall surface adjacent to the (b)(4) pipelines, located outside the (b)(4) room within the HVAC area.\nAll equipment and associated operational areas should follow a reliable, comprehensive preventive maintenance program. This program should be designed to ensure sustained operational integrity through the systematic implementation of validated cleaning and disinfection protocols, as well as the proactive replacement of components before they deteriorate or degrade. Maintenance and change management procedures should prevent practices that may compromise equipment or introduce contamination risks.\nAseptic processes need to be designed to minimize exposure of sterile articles to potential contamination hazards. A suitable monitoring system is critical to maintain appropriate environmental conditions throughout your (b)(4) and cleanrooms. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\nYour response states existing procedures \"did not adequately define acceptable hand positioning, intervention speed, first-air protection requirements, rejection criteria for potentially affected exposed units, or required actions following airflow interruption\" and acknowledges “equipment design and ergonomic limitations within the (b)(4)”. Additionally, you state you will not resume operations until “successful aseptic process simulation run incorporating all listed interventions under worst-case conditions are completed”. Furthermore, you commit to updating procedures for (b)(4) sanitization and cleaning to include sterile (b)(4) and sterile wipes. Your response also states that remediations were made to equipment, including repairing all sealant joints in the (b)(4), smoothing internal machine surfaces to meet cleanability requirements, and updating maintenance checklists to include criteria for wear, damage, smoothness, cleanability, and material suitability.\nYour response is inadequate. You do not provide sufficient detail including deliverables on your third-party risk assessment of all aseptic filling lines. Additionally, your response does not sufficiently address the lack of oversight of operator aseptic behavior, equipment cleaning and maintenance, various manual activities, and intervention ergonomics.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn your response to this letter, provide the following:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nA comprehensive, independent risk assessment by a qualified consultant of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including, but not limited to, the following:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\no Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\nA detailed remediation plan from the independent consultant with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms, the specific barrier system to be used (e.g., Restricted Access Barrier, (b)(4)), and associated timelines. Also, describe your plans for qualification and validation of your extensively remediated operations.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nDrug Recall and Drug Production Suspended\nOn June 18, 2026, FDA held a teleconference with you recommending you consider removing any batches of sterile drugs currently in distribution from the U.S. market. On June 19, 2026, you agreed to recall all sterile drug products.\nWe acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market.\nYou are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance prior to resumption of any manufacturing operations. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Reliance Life Sciences Private Limited, Navi Mumbai, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter1. Identify your written response with FEI 3009510975 and ATTN: Claire Minden in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: Dr. Sandhya Narasimhan\nusagent1@masuuglobal.com\n___________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Reliance Life Sciences Private Limited","reliance-life-sciences-private-limited-730801-08182026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freliance-life-sciences-private-limited-730801-08182026","2026-10-26T08:09:48.525245+00:00","2026-09-01","730801","Mr. Santhosh Mathai","2026-09-07T05:14:54.57+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-26-117","2026-08-18",{"id":305,"raw":306,"subject":310,"body_html":311,"body_text":312,"firm_name":313,"letter_id":314,"created_at":18,"fei_number":19,"letter_url":315,"updated_at":316,"action_type":22,"case_status":23,"posted_date":317,"marcs_cms_no":318,"product_type":108,"closeout_date":19,"issuing_office":11,"recipient_name":319,"body_fetched_at":320,"delivery_method":282,"recipient_title":19,"reference_number":321,"action_taken_date":322,"medical_device_id":19,"response_letter_date":19},118,[307,308,309,11,310,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fumendra-life-sciences-private-limited-721752-06022026\">Umendra Life Sciences Private Limited\u003C\u002Fa>","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-91\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ankur Sharma Sr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager – Quality \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Umendra Life Sciences Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>New Survey No. 211, Village Account No. 170 Old Block\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Survey No. 158, Bavla, Taulka Mauje\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-91\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Sharma:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Umendra Life Sciences Private Limited, FEI 3035187076, at New Survey No. 211, Village Account No. 170 Old Block \u002F Survey No. 158, Bavla, Taulka Mauje, Amipura, Ahmedabad, Gujarat.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products labeled to contain the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This drug product is also labeled and formulated to contain the inactive ingredient talc. For one of the drug products, the formulation is composed of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing talc in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and the incidence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, potentially linked to asbestos contamination of the talc.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The \u003Cstrong>(b)(4)\u003C\u002Fstrong> you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or \u003Cstrong>(b)(4)\u003C\u002Fstrong> area). Your drug products are considered a higher-risk drugs as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area.\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). In addition, you did not demonstrate that your firm’s QU has adequate oversight of your contract testing facility. Your QU approved and accepted talc for use in drug manufacturing without ensuring compliance with CGMP.\u003C\u002Fp>\u003Cp>Your QU failed to assure that contract facilities are testing according to your procedures which require you to follow current United States Pharmacopeia (USP) specifications and that results are supported by sufficient information to provide an accurate determination of compliance. In particular, your QU did not adequately review or approve methods used by your contract laboratory, and review and approve data to ensure results are supported by accurate data.\u003C\u002Fp>\u003Cp>The tests included in the specification were not performed according to current USP. You did not conduct testing using Atomic Absorption for Calcium and Assay Content of Magnesium as required by USP. For identification and asbestos testing conducted, the documentation does not fully support results reported. Current USP identification procedure acceptance criteria is “the IR spectrum of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of it exhibits maxima at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1, at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1, and at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1” and absence of asbestos procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite, chlorite and serpentines, through scale expansions of spectra at the required wavenumbers of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1, and in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1. Your instrument reports for the identification spectroscopy report was from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 and did not identify peak maxima wavenumbers as required in USP for the one identification test performed. For tests conducted for asbestos, data does not include expansion of spectra at the required wavenumber of \u003Cstrong>(b)(4)\u003C\u002Fstrong>cm-1 and the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 was covered in by the spectral analysis. Your identification spectra does not evaluate for the presence of serpentines between wavenumbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1.\u003C\u002Fp>\u003Cp>Furthermore, your specifications for talc components did not include testing for multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and lacks identification procedures \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations, including an evaluation of your contract facility qualification program, to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>Gap analysis for your approved specifications, test methods and laboratory practices against the USP, where applicable, for drug components (active and inactive) and those conducted at your contract facility. If notable differences are observed, provide an impact analysis and corrective actions, which may include retrospective testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not demonstrated that you appropriately tested incoming talc drug components or validated and established the reliability of your component supplier’s test analyses at appropriate intervals for talc.\u003C\u002Fp>\u003Cp>You provided records to demonstrate you had conducted identity testing pursuant to the applicable USP test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification \u003Cstrong>(b)(4)\u003C\u002Fstrong>). A representative certificates of analysis (COA) indicated that the material supplied appears to be Indian Pharmacopeia (IP) grade and sufficient information was not submitted to support that materials meet USP monograph standards. Our review of the IP talc monograph revealed that the IP provides less details and lacks some critical requirements such as assay and several impurities (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you relied on the COA from your suppliers and failed to establish the reliability of each of your suppliers’ COA for component specifications and characteristics at appropriate intervals. Although 21 CFR 211.84(d)(2) provides for some reliance on a COA from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Reformulation to No Longer Use Talc in High-Risk Dosage Forms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In response to our request for records you indicated that you are in the process of reformulating to remove talc as an ingredient and replace with corn starch. In response to this letter provide an update on your talc.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violation promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Umendra Life Sciences Private Limited, New Survey No. 211, Village Account No. 170 Old, Block \u002F Survey No. 158, Bavla, Taluka Mauje, Amipura, Ahmedabad, Gujarat into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3035187076 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\u003Cp>\u003Cstrong>3\u003C\u002Fstrong> https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-91\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ankur Sharma Sr.\n\nRecipient Title\n\nGeneral Manager – Quality\n\nUmendra Life Sciences Private Limited\n\nNew Survey No. 211, Village Account No. 170 Old Block\n\nSurvey No. 158, Bavla, Taulka Mauje\n\nAhmedabad 382220\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-91\nJune 2, 2026\nDear Mr. Sharma:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Umendra Life Sciences Private Limited, FEI 3035187076, at New Survey No. 211, Village Account No. 170 Old Block \u002F Survey No. 158, Bavla, Taulka Mauje, Amipura, Ahmedabad, Gujarat.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm manufactures OTC (b)(4) drug products labeled to contain the active ingredient (b)(4). This drug product is also labeled and formulated to contain the inactive ingredient talc. For one of the drug products, the formulation is composed of more than (b)(4)% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4), potentially linked to asbestos contamination of the talc.3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or (b)(4) area). Your drug products are considered a higher-risk drugs as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the (b)(4) area.\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). In addition, you did not demonstrate that your firm’s QU has adequate oversight of your contract testing facility. Your QU approved and accepted talc for use in drug manufacturing without ensuring compliance with CGMP.\nYour QU failed to assure that contract facilities are testing according to your procedures which require you to follow current United States Pharmacopeia (USP) specifications and that results are supported by sufficient information to provide an accurate determination of compliance. In particular, your QU did not adequately review or approve methods used by your contract laboratory, and review and approve data to ensure results are supported by accurate data.\nThe tests included in the specification were not performed according to current USP. You did not conduct testing using Atomic Absorption for Calcium and Assay Content of Magnesium as required by USP. For identification and asbestos testing conducted, the documentation does not fully support results reported. Current USP identification procedure acceptance criteria is “the IR spectrum of a (b)(4) of it exhibits maxima at (b)(4) ± (b)(4) cm–1, at (b)(4) ± (b)(4) cm–1, and at (b)(4) ± (b)(4) cm–1” and absence of asbestos procedure (b)(4) by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite, chlorite and serpentines, through scale expansions of spectra at the required wavenumbers of (b)(4) cm-1, and in the range of (b)(4) cm-1 to (b)(4) cm-1. Your instrument reports for the identification spectroscopy report was from (b)(4) cm–1 to (b)(4) cm–1 and did not identify peak maxima wavenumbers as required in USP for the one identification test performed. For tests conducted for asbestos, data does not include expansion of spectra at the required wavenumber of (b)(4)cm-1 and the range of (b)(4) cm-1 to (b)(4) cm-1 was covered in by the spectral analysis. Your identification spectra does not evaluate for the presence of serpentines between wavenumbers (b)(4) cm–1 and (b)(4) cm–1.\nFurthermore, your specifications for talc components did not include testing for multiple impurities (e.g., limits of (b)(4)) and lacks identification procedures (b)(4) and (b)(4). Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations, including an evaluation of your contract facility qualification program, to evaluate adherence to appropriate practices.\nGap analysis for your approved specifications, test methods and laboratory practices against the USP, where applicable, for drug components (active and inactive) and those conducted at your contract facility. If notable differences are observed, provide an impact analysis and corrective actions, which may include retrospective testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm has not demonstrated that you appropriately tested incoming talc drug components or validated and established the reliability of your component supplier’s test analyses at appropriate intervals for talc.\nYou provided records to demonstrate you had conducted identity testing pursuant to the applicable USP test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification (b)(4)). A representative certificates of analysis (COA) indicated that the material supplied appears to be Indian Pharmacopeia (IP) grade and sufficient information was not submitted to support that materials meet USP monograph standards. Our review of the IP talc monograph revealed that the IP provides less details and lacks some critical requirements such as assay and several impurities (e.g., (b)(4)). Additionally, you relied on the COA from your suppliers and failed to establish the reliability of each of your suppliers’ COA for component specifications and characteristics at appropriate intervals. Although 21 CFR 211.84(d)(2) provides for some reliance on a COA from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\nReformulation to No Longer Use Talc in High-Risk Dosage Forms\nIn response to our request for records you indicated that you are in the process of reformulating to remove talc as an ingredient and replace with corn starch. In response to this letter provide an update on your talc.\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in (b)(4).\nUse of Contract Manufacturers\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violation promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Umendra Life Sciences Private Limited, New Survey No. 211, Village Account No. 170 Old, Block \u002F Survey No. 158, Bavla, Taluka Mauje, Amipura, Ahmedabad, Gujarat into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3035187076 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\n3 https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc","Umendra Life Sciences Private Limited","umendra-life-sciences-private-limited-721752-06022026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fumendra-life-sciences-private-limited-721752-06022026","2026-10-26T08:10:17.28862+00:00","2026-06-09","721752","Mr. Ankur Sharma Sr.","2026-08-19T04:38:23.105+00:00","320-26-91","2026-06-02",{"id":324,"raw":325,"subject":80,"body_html":329,"body_text":330,"firm_name":331,"letter_id":332,"created_at":184,"fei_number":19,"letter_url":333,"updated_at":334,"action_type":22,"case_status":23,"posted_date":335,"marcs_cms_no":336,"product_type":337,"closeout_date":19,"issuing_office":267,"recipient_name":338,"body_fetched_at":339,"delivery_method":282,"recipient_title":19,"reference_number":19,"action_taken_date":340,"medical_device_id":19,"response_letter_date":19},1441,[326,327,328,267,80,13,13,13],"\u003Ctime datetime=\"2024-05-28T13:20:00Z\">05\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-09T04:00:00Z\">05\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024\">Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Zachary Bush\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4351 Seminole Trail\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charlottesville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22153-2823\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 9, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #667601\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Bush,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>FDA Tested Samples\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>FDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>Microorganisms identified included \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii)\u003C\u002Fem>, and \u003Cem>Paenibacillus sp.\u003C\u002Fem> The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\u003C\u002Fp>\n\n\u003Cp>On September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\u003C\u002Fp>\n\n\u003Cp>On September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp.\u003C\u002Fem> (primarily \u003Cem>B. malikii\u003C\u002Fem>), and \u003Cem>Paenibacillus sp\u003C\u002Fem>., as noted on the following FDA website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fp>\n\n\u003Cp>Your firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\u003C\u002Fp>\n\n\u003Cp>You also stated during the inspection that you add \u003Cstrong>(b)(4)\u003C\u002Fstrong> to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> may \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure that have led to \u003Cstrong>(b)(4)\u003C\u002Fstrong> documented and therefore, it is not possible to establish minimum levels that are safe.\u003C\u002Fp>\n\n\u003Cp>In your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\u003C\u002Fp>\n\n\u003Cp>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\u003C\u002Fli>\n\t\u003Cli>Procedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. You may refer to FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>Adulterated &amp; Misbranded Dietary Supplements\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Adulterated Low Acid Canned Food Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\u003C\u002Fp>\n\n\u003Cp>1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\u003C\u002Fp>\n\n\u003Cp>2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have initiated contact with a process authority, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge that you have initiated actions. However, this violation remains uncorrected.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Violations of Dietary Supplement CGMPs\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of dietary supplement CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\u003C\u002Fp>\n\n\u003Cp>For your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or components \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 111.70(b)(3). \u003Cstrong>(b)(4)\u003C\u002Fstrong> is susceptible to having contaminants not limited to microorganisms and heavy metals.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You then used this \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\u003C\u002Fli>\n\t\u003Cli>The identity and weight or measurement of water and \u003Cstrong>(b)(4)\u003C\u002Fstrong> components in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively (21 CFR 111.260(e)).\u003C\u002Fli>\n\t\u003Cli>Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you use in the manufacturing or testing of your Ion Gut Support.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Misbranding of Dietary Supplement Products\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>The Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: \u003Cstrong>(b)(4) \u003C\u002Fstrong>purified water,\u003Cstrong> (b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Each ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>In your response, you state your components, other than humic extract,&nbsp;are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (which is a product that consists of: \u003Cstrong>(b)(4)\u003C\u002Fstrong> are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\u003C\u002Fli>\n\t\u003Cli>A light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\u003C\u002Fli>\n\t\u003Cli>The title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\u003C\u002Fli>\n\t\u003Cli>There is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\u003C\u002Fp>\n\n\u003Cp>3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>In your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robin M. Rivers\u003Cbr>\nActing Program Division Director\u003Cbr>\nPhiladephia District Office\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nRobin.Rivers@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Zachary Bush\n\nRecipient Title\n\nOwner\n\nBiomic Sciences, LLC dba ION Intelligence of Nature\n\n4351 Seminole Trail\n\nCharlottesville, VA 22153-2823\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nMay 9, 2024\n\nWARNING LETTER\n\nCMS #667601\n\nDear Dr. Bush,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\n\nAdulterated Human Drugs\n\nFDA Tested Samples\n\nFDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\n\nFDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\n\nFDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\n\nMicroorganisms identified included Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp. The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\n\nOn September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\n\nOn September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp., as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\n\nDrug CGMP Violations\n\nThe inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\n\nYou also stated during the inspection that you add (b)(4) to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing (b)(4) may (b)(4). Levels of (b)(4) exposure that have led to (b)(4) documented and therefore, it is not possible to establish minimum levels that are safe.\n\nIn your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\n\nIn response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\n\nAdequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\n\nAdequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\n\nProcedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\n\nAdequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\n\nEstablishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\n\nAdequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\n\nAdditionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\n\nYour firm’s quality systems are inadequate. You may refer to FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system1 audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdulterated & Misbranded Dietary Supplements\n\nAdulterated Low Acid Canned Food Dietary Supplements\n\nThe inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\n\nAs a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\n\n1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\n\n2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\n\nYour response indicates that you have initiated contact with a process authority, (b)(4). We acknowledge that you have initiated actions. However, this violation remains uncorrected.\n\nScheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\n\nViolations of Dietary Supplement CGMPs\n\nThe inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of dietary supplement CGMP requirements are as follows:\n\n1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\n\nFor your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components (b)(4), used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for (b)(4) or components (b)(4) that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for (b)(4), as required by 21 CFR 111.70(b)(3). (b)(4) is susceptible to having contaminants not limited to microorganisms and heavy metals.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\n\n2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\n\n3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place (b)(4) or (b)(4), used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received (b)(4) from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on (b)(4), to manufacture (b)(4). You then used this (b)(4) in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\n\nWe received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “(b)(4)” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\n\n4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\n\nThe date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\n\nThe identity and weight or measurement of water and (b)(4) components in the (b)(4) and (b)(4) respectively (21 CFR 111.260(e)).\n\nDocumentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for (b)(4). However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\n\n5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your (b)(4), which you use in the manufacturing or testing of your Ion Gut Support.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your (b)(4). Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nMisbranding of Dietary Supplement Products\n\nIn addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\n\nThe Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: (b)(4) purified water, (b)(4).\n\nEach ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\n\nIn your response, you state your components, other than humic extract, are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the (b)(4) product (which is a product that consists of: (b)(4) are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\n\n2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\n\nThe Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\n\nA heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\n\nA light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\n\nA heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\n\nThe title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\n\nThere is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\n\nIn your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\n\n3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\n\nIn your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\n\n4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\n\nIn your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\n\nYour written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRobin M. Rivers\n\nActing Program Division Director\n\nPhiladephia District Office\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration\n\nRobin.Rivers@fda.hhs.gov\n\n___________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Biomic Sciences, LLC dba ION Intelligence of Nature","biomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","2026-10-26T08:08:05.177812+00:00","2024-05-28","667601","Food & Beverages","Dr. Zachary Bush","2026-08-20T00:03:55.93+00:00","2024-05-09",{"id":342,"raw":343,"subject":347,"body_html":348,"body_text":349,"firm_name":350,"letter_id":351,"created_at":18,"fei_number":19,"letter_url":352,"updated_at":353,"action_type":22,"case_status":23,"posted_date":354,"marcs_cms_no":355,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":356,"body_fetched_at":357,"delivery_method":71,"recipient_title":19,"reference_number":358,"action_taken_date":359,"medical_device_id":19,"response_letter_date":19},155,[344,345,346,11,347,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsourav-k-mishra-md-all-india-institute-medical-sciences-724881-04292026\">Sourav K. Mishra, M.D. \u002F All India Institute of Medical Sciences\u003C\u002Fa>","In Vivo Bioavailability-Bioequivalence Studies – Clinical","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-04-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sourav K. Mishra, M.D. \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sourav K. Mishra, M.D. \u002F All India Institute of Medical Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sijua, Patrapada\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bhubaneswar\u003C\u002Fspan> \u003Cspan>751019\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Odisha\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-04-02\u003C\u002Fp>\u003Cp>Dear Dr. Mishra:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at All India Institute of Medical Sciences in Bhubaneswar, Odisha, India, between March 17 and March 20, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm\u003Csup>2\u003C\u002Fsup> dose) (Doxorubicin-Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report and the documents submitted with that report, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a clinical investigator, you are required to ensure that your clinical investigations are conducted in accordance with the investigational plan. The investigational plan for Protocol 0270-22\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> required you to prohibit the use of cytochrome P450 CYP3A4 and CYP2D6 inhibitors to subjects during the entire study duration, and before baseline for at least five half-lives of the given drug, if given prior to the first dose of the study intervention.\u003C\u002Fp>\u003Cp>You failed to adhere to this requirement. Specifically, all three enrolled subjects were orally administered Aprecap (aprepitant), a moderate inhibitor of CYP3A4, during the study. Examples of these failures include:\u003C\u002Fp>\u003Cp>a. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed the informed consent on October 17, 2023, and was administered investigational product on November 1, 2023 (Period I) and on December 1, 2023 (Period II). However, this subject was administered Aprecap between November 1 and November 3, 2023, and between December 1 and December 3, 2023.\u003C\u002Fp>\u003Cp>b. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed the informed consent on October 30, 2023, and was administered investigational product on November 10, 2023 (Period I). However, this subject was administered Aprecap between November 10 and November 12, 2023.\u003C\u002Fp>\u003Cp>c. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed the informed consent on November 16, 2023, and was administered investigational product on November 29, 2023 (Period I) and on December 27, 2023 (Period II). However, this subject was administered Aprecap between November 29 and December 1, 2023, and between December 27 and December 29, 2023.\u003C\u002Fp>\u003Cp>During the inspection, you stated that it is the oncology department’s usual practice to administer Aprecap 125\u002F80 capsules before a patient receives chemotherapy. You also stated that you would pay closer attention to the protocol requirements related to prohibited medication. While we acknowledge your statements made during the inspection, your statements are inadequate because you have not provided sufficient details about how you, as a clinical investigator, will prevent similar violations in the future.\u003C\u002Fp>\u003Cp>We emphasize that failure to conduct the clinical investigation in accordance with the protocol raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site. Specifically, as stated in the protocol, Cytochrome P450 CYP3A4 and CYP2D6 inhibitors were prohibited during the study as they affect the pharmacokinetics of the study intervention, which is the primary objective of the clinical trial. In addition, the prohibited medication can interfere with the investigational product metabolism, which can increase the risk of side effects and reduce investigational product efficacy. As the clinical investigator, you are responsible for ensuring compliance with the protocol requirements for prohibited and concomitant medications.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\u003C\u002Fp>\u003Cp>You failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\u003C\u002Fp>\u003Cp>During the inspection, you stated that you understood the FDA investigator’s statements that you are ultimately responsible for all documentation provided to study subjects, regardless of who authored the informed consent form, and that safety or efficacy claims of the test drug were not allowed in the informed consent form. While we acknowledge your statement of understanding, your statement is inadequate because you have not provided sufficient details about how you, as a clinical investigator, will prevent similar violations in the future.\u003C\u002Fp>\u003Cp>We emphasize that as the clinical investigator, you are responsible for ensuring that legally effective informed consent is obtained from subjects before their enrollment. Your failure to obtain informed consent before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\u003C\u002Fp>\u003Cp>We acknowledge that a Form FDA 483 citing the inspectional findings described in this letter was not issued, however, these concerns were discussed with your staff at the conclusion of the inspection.\u003C\u002Fp>\u003Cp>We emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, both to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol, and your failure to seek informed consent in accordance with the requirements in 21 CFR part 50, raise significant concerns about your protection of study subjects enrolled at your site and raise concerns about the reliability of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>David Burrow Digitally signed by David Burrow\u003Cbr>Date: 4\u002F29\u002F2026 01:48:38 PM EDT\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Protocol 0270-22 (Version: 2.1, Document Release Date: 29-Nov-2022) was effective when the prohibited medication and study intervention were administered to the subjects.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-04-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSourav K. Mishra, M.D.\n\nSourav K. Mishra, M.D. \u002F All India Institute of Medical Sciences\n\nSijua, Patrapada\n\nBhubaneswar 751019\n\nOdisha\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-04-02\nDear Dr. Mishra:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at All India Institute of Medical Sciences in Bhubaneswar, Odisha, India, between March 17 and March 20, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm2 dose) (Doxorubicin-Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nFrom our review of the FDA Establishment Inspection Report and the documents submitted with that report, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.1 We wish to emphasize the following:\n1. You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\nAs a clinical investigator, you are required to ensure that your clinical investigations are conducted in accordance with the investigational plan. The investigational plan for Protocol 0270-222 required you to prohibit the use of cytochrome P450 CYP3A4 and CYP2D6 inhibitors to subjects during the entire study duration, and before baseline for at least five half-lives of the given drug, if given prior to the first dose of the study intervention.\nYou failed to adhere to this requirement. Specifically, all three enrolled subjects were orally administered Aprecap (aprepitant), a moderate inhibitor of CYP3A4, during the study. Examples of these failures include:\na. Subject (b)(6) signed the informed consent on October 17, 2023, and was administered investigational product on November 1, 2023 (Period I) and on December 1, 2023 (Period II). However, this subject was administered Aprecap between November 1 and November 3, 2023, and between December 1 and December 3, 2023.\nb. Subject (b)(6) signed the informed consent on October 30, 2023, and was administered investigational product on November 10, 2023 (Period I). However, this subject was administered Aprecap between November 10 and November 12, 2023.\nc. Subject (b)(6) signed the informed consent on November 16, 2023, and was administered investigational product on November 29, 2023 (Period I) and on December 27, 2023 (Period II). However, this subject was administered Aprecap between November 29 and December 1, 2023, and between December 27 and December 29, 2023.\nDuring the inspection, you stated that it is the oncology department’s usual practice to administer Aprecap 125\u002F80 capsules before a patient receives chemotherapy. You also stated that you would pay closer attention to the protocol requirements related to prohibited medication. While we acknowledge your statements made during the inspection, your statements are inadequate because you have not provided sufficient details about how you, as a clinical investigator, will prevent similar violations in the future.\nWe emphasize that failure to conduct the clinical investigation in accordance with the protocol raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site. Specifically, as stated in the protocol, Cytochrome P450 CYP3A4 and CYP2D6 inhibitors were prohibited during the study as they affect the pharmacokinetics of the study intervention, which is the primary objective of the clinical trial. In addition, the prohibited medication can interfere with the investigational product metabolism, which can increase the risk of side effects and reduce investigational product efficacy. As the clinical investigator, you are responsible for ensuring compliance with the protocol requirements for prohibited and concomitant medications.\n2. You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\nAs a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,3 no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\nYou failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\nDuring the inspection, you stated that you understood the FDA investigator’s statements that you are ultimately responsible for all documentation provided to study subjects, regardless of who authored the informed consent form, and that safety or efficacy claims of the test drug were not allowed in the informed consent form. While we acknowledge your statement of understanding, your statement is inadequate because you have not provided sufficient details about how you, as a clinical investigator, will prevent similar violations in the future.\nWe emphasize that as the clinical investigator, you are responsible for ensuring that legally effective informed consent is obtained from subjects before their enrollment. Your failure to obtain informed consent before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\nWe acknowledge that a Form FDA 483 citing the inspectional findings described in this letter was not issued, however, these concerns were discussed with your staff at the conclusion of the inspection.\nWe emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, both to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol, and your failure to seek informed consent in accordance with the requirements in 21 CFR part 50, raise significant concerns about your protection of study subjects enrolled at your site and raise concerns about the reliability of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely yours,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nDavid Burrow Digitally signed by David Burrow\nDate: 4\u002F29\u002F2026 01:48:38 PM EDT\n_________________________\n1 In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\n2 Protocol 0270-22 (Version: 2.1, Document Release Date: 29-Nov-2022) was effective when the prohibited medication and study intervention were administered to the subjects.\n3 The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.","Sourav K. Mishra, M.D. \u002F All India Institute of Medical Sciences","sourav-k-mishra-md-all-india-institute-medical-sciences-724881-04292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsourav-k-mishra-md-all-india-institute-medical-sciences-724881-04292026","2026-10-26T08:10:01.76731+00:00","2026-05-19","724881","Sourav K. Mishra, M.D.","2026-08-19T04:41:52.675+00:00","26-HFD-45-04-02","2026-04-29",17,{"510k":362,"classification":363,"enforcement":364,"event":365,"event_backfill":366,"pma":367,"warning_letter":368},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]